



(51) International Patent Classification:

*A61K 9/127* (2006.01)     *A61P 31/06* (2006.01)  
*A61K 47/26* (2006.01)     *A61K 31/06* (2006.01)  
*A61K 39/04* (2006.01)

(21) International Application Number:

PCT/EP2012/050080

(22) International Filing Date:

4 January 2012 (04.01.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

11150072.4     4 January 2011 (04.01.2011)     EP  
11183487.5     30 September 2011 (30.09.2011)     EP

(71) Applicant (for all designated States except US):

**ARCHIVEL FARMA, SL** [ES/ES]; Ctra. de mata Edifici Matamar 2 Pol., Industrial Matarrocafonda, E-08304 Mataró (Barcelona) (ES).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CARDONA, Pere Joan** [ES/ES]; c/Osona, 3 Àtic 1era, E-08023 Barcelona (ES). **AMAT, Isabel** [ES/ES]; c/Osona, 3 Àtic 1era, E-08023 Barcelona (ES). **REYES, Blanca** [ES/ES]; c/Arànsers, 3 2, E-08830 Sant Boi de Llobregat (ES). **SELGA, Ariadna** [ES/ES]; c/Consell de Cent, 111 4-1, E-08015 Barcelona (ES). **AMAT, Mercè** [ES/ES]; c/Vic, 20 5-2, E-08006 Barcelona (ES).

(74) Agents: **RENKEN, Joachim** et al.; (Hoffmann.Eitle), Arabellastrasse 4, 81925 Munich (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with amended claims (Art. 19(1))
- with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))



WO 2012/093137 A1

(54) Title: LIPOSOME FORMULATION SUITABLE FOR TREATING OR PREVENTING TUBERCULOSIS

(57) Abstract: The invention provides liposome formulations comprising fragments from a Mycobacterium tuberculosis-complex strain, it also provides a Mycobacterium tuberculosis-complex strain, fragments of which may be incorporated into selected embodiments of the liposome formulation. The invention further provides suspensions and pharmaceutical compositions comprising the liposome formulations. Furthermore, it discloses the use of the liposome formulations for use in a method of treatment of the human or animal body by therapy, in particular for use in a method of treating or preventing tuberculosis, such as in preventing latent tuberculosis or in tuberculosis prophylaxis, optionally in combination therapy. The formulation of this invention contains sucrose and/or has a lower average particle size than conventional liposome-based agents of tuberculosis therapy, resulting in higher bioavailability and efficiency.

152 486 n17

Liposome formulation suitable for treating or preventing tuberculosis5 Introduction and background artField of the Invention

10 The present invention provides liposome formulations comprising fragments from a *Mycobacterium tuberculosis*-complex strain, as well as suspensions and pharmaceutical compositions comprising these formulations and their respective use in a method of treatment, particularly for treating or preventing tuberculosis. The formulation of this invention contains sucrose and/or has a lower average particle size than conventional liposome-based agents of tuberculosis therapy, resulting in higher bioavailability and  
15 efficiency.

Background Art

20 Tuberculosis is a chronic infectious disease caused by the *Mycobacterium tuberculosis*-complex (MTB-C) bacilli, which includes the *Mycobacterium* species *M. tuberculosis*, *M. bovis*, *M. microti* and *M. africanum*. The main distinctive feature of the mycobacterial cellular envelope is the thick and waxy cell wall. The properties of the cell wall barrier also contribute to the intracellular survival of the organism by acting as a direct modulator in the immunological reactions between the host and MTB-C bacilli. The envelope consists  
25 of two distinct parts, the plasma membrane and, around it, the wall. The cell wall is a skeleton formed by a covalently linked structure of peptidoglycan, with a branched-chain polysaccharide, the arabinogalactan, attached by phosphodiester bonds. The arabinogalactan distal ends are esterified with high-molecular weight fatty acids, the mycolic acids, of sizes and structures unique to mycobacteria.

30

According to the World Health Organization, 9,000,000 new cases of people manifesting the disease are recorded worldwide every year and about 2,000,000 people die. It is considered that there are more than 2,700,000,000 infected people worldwide and that 90 - 100 million more new infections are generated each year.

35

Various vaccines against tuberculosis based on cell wall fragments of virulent or avirulent strains of *Mycobacterium* are described in the state of the art. The vaccine which is

currently used in the preventive treatment against tuberculosis is based on bacteria of the strain called BCG (Bacillus Calmette-Guerin), an attenuated variant of *M. bovis*. It is also known that the adjuvant used in the composition of the vaccine can greatly influence the effectiveness thereof.

5

Trehalose mycolates, particularly trehalose dimycolate, are the most bioactive lipids in *M. tuberculosis* extracts, inducing a proinflammatory cascade that influences granuloma formation. It should be noted that no bibliographic data exist on the amount of these compounds present in the cell wall of *M. tuberculosis*. Any sample derived of this species has a high biological complexity. Therefore, to perform quantitative analysis, aggressive, complex and long purification steps would be required, resulting in too low amounts of the purified compound to perform further structural analyses. This is the reason why no published data exist about the exact percent of each compound in the cell wall of *M. tuberculosis*. Several glycolipids are typical constituents of MTB-C cells, such as liporabinomannan. Lipoarabinomannan is associated with MTB-C virulence.

10  
15

E. Ribi *et al.*, Nature 1963, 198, pages 1214 to 1215, describe the immunization assays performed with a composition comprising cell wall fragments of the avirulent Bacillus Calmette Guerin (BCG) strain and mineral oil. Said fragments are obtained by homogenisation of a culture of said strain in mineral oil. The composition is more effective than the conventional vaccine (BCG). Nevertheless, it is described in the same article that the cell wall fragments do not induce any immunological response when they are obtained by homogenisation in water and in the absence of the mineral oil.

20

D.P. Pal *et al.*, Indian J. Med. Res. 1977, 65, pages 340 to 345, describe a vaccine prepared with cell wall fragments of the virulent H37Rv strain and mineral oil. In this case the cell wall fragments are obtained by means of homogenisation of the dead cells in aqueous phase, and the mineral oil is subsequently added to the composition. It is also described that the cell wall fragments homogenised in aqueous phase are not immunogenic and that the presence of mineral oil is necessary for the vaccine to be effective.

25  
30

G.K. Khuller *et al.*, Folia Microbiol., 1992, 37, pages 407 to 412, describe the protective efficacy of different fractions of the cell wall of the avirulent H37Ra strain of *M. tuberculosis* formulated with Freund's incomplete adjuvant, which also includes mineral oil.

35

E.M. Agger et al., Scand. J. Immunol., 2002, 56, pages 443 to 447, describe vaccines comprising cell wall fragments of the virulent H37Rv strain, which are effective when they include the cationic surfactant dimethyldioctadecylammonium bromide as an adjuvant. It is also described that the assays conducted with homogenised *M. tuberculosis* bacilli which do not contain the mentioned adjuvant do not generate levels of resistance against tuberculosis in the mouse model.

I.M. Orme Vaccine, 2006, 24, pages 2 to 19, which is a review article of vaccines against tuberculosis, describes that the conventional Bacillus Calmette-Guerin (BCG) based vaccine is essentially ineffective in protecting adult people against tuberculosis.

Individuals who may benefit from a treatment or prophylaxis related to tuberculosis can be grouped in the following four sub-groups:

- (I) Individuals who are not exposed to the disease. Prophylactic vaccination can prevent infection of such individual.
- (II) Individuals who are exposed to the disease but not yet infected. The skin tuberculin test (TST) is negative. Primary prophylaxis can prevent infection of such individuals.
- (III) Individuals with latent tuberculosis who are not ill. The risk of the outbreak of the disease can be lowered by applying chemotherapy. The chemotherapy also provides the advantage that these individuals basically cease being high risk sources of the infection.
- (IV) Individuals who are ill, i.e. suffering from the disease, normally with primary forms of the disease, but little or not contagious. Chemotherapy avoids that these individuals become contagious.

Once the infection has started, the state of the art describes various treatments for defending the development of active tuberculosis in infected individuals, i.e. individuals with latent tuberculosis.

For example, in the patent application EP2196473 A1, it is described that, for treating tuberculosis in infected individuals, those who have not yet developed the disease as well as those who have already developed the disease, various drugs, including isoniazide, can be administered for a time extending for several months.

In the patent application ES 2231037 A1 the use of an immunotherapeutic agent is described that comprises cell fragments of a virulent strain of *Mycobacterium tuberculosis*-complex (MTB-C) for the preparation of a medicament for treatment of tuberculosis in infected individuals in combination with other drugs, like isoniazide or rifampicin. This patent application also discloses a method for the preparation of an immunotherapeutic agent comprising cell wall fragments of a strain of MTB-C.

As outlined in WO 2010/031883 A1, the transmission of the latent tuberculosis infection occurs mainly through breathing aerosols infected with *M. tuberculosis*. Therefore, persons in direct contact with patients suffering pulmonary tuberculosis, and thus that are able to disseminate infected aerosols, such as persons who live together or have any other type of intense or frequent contact with them, are considered a risk group.

Currently, the primary prophylaxis of the infection that is administered normally to group I individuals (as above) is a primary chemoprophylaxis based on daily administration of isoniazide in a dose of 5 mg/kg without exceeding 300 mg/day. This treatment is indicated in all individuals of any age who are TST negative, who live together and/or have any other type of close contact with infected individuals. In this case, the chemoprophylaxis needs to be maintained for three months after having ceased the contact with the infectious source or after the source has ceased being infective. However, chemoprophylaxis can in some cases lead to secondary unwanted effects, as described by Martínez *et al.*, Arch. Bronchoneumol., 2005, 41(1), pages 27-33.

Medications comprising fragments of a virulent *M. tuberculosis*-complex (MTB-C) strain have been described for example in EP1690549 B1, EP2090318 A1 and PCT/ES2009/000436. EP2090318 A1 and PCT/ES2009/000436 disclose pharmaceutical compositions comprising fragments of a virulent *M. tuberculosis*-complex (MTB-C) strain for the use as a medicament suitable for prophylactic prevention of tuberculosis, optionally in combination with other drugs. On the other hand, EP1690549 B1 discloses pharmaceutical compositions suitable for the treatment of tuberculosis, comprising MTB-C fragments, optionally in combination with other drugs.

It has been reported in the patent application EP 2090318 A1 that the administration of a drug comprising an agent based on cell wall fragments of a virulent strain of MTB-C is able to induce a Th1 type interferon- $\gamma$  generating response against *M. tuberculosis*-specific antigens. Said antigens include Ag85B and Ag85A, which are part of the complex Ag85, consisting of a family of low molecular weight proteins playing a decisive role in the

biosynthesis of the cell wall and produced in considerable amounts when the bacterial cultivation is in the logarithmic growth (log) phase. It has further been reported in EP 2090318 A1 that the conventional Bacillus Calmette-Guerin (BCG) based vaccine does not generate an immunoprotective response against antigens of complex Ag85. The production of interferon- $\gamma$  by the specific lymphocytes has a key role: It enables the infected macrophages to stop the growth of the bacilli (North & Young, Ann. Rev. Immunol., 2004, 22:599-623).

10 The World health Organization has recognized that the risk of developing tuberculosis (TB) is estimated to be between 20-37 times greater in people living with HIV than among those without HIV infection. An overview is given in "Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings" WHO Guidelines 2011, ISBN: 978 92 4 150070 8). However, the isoniazid preventive therapy is not a vaccination that would provide long-lasting protection to HIV positive individuals. Rather, the isoniazid needs to be administered regularly, and isoniazid resistance corroborates this therapy. Thus, there remains a need of providing more powerful preventive and therapeutic treatments for HIV positive human subjects.

## 20 Object of the Invention

The object of the present invention is the provision of an improved agent suitable for preventing or treating tuberculosis, such as in prophylaxis of latent tuberculosis, primary prophylaxis, and/or treatment of latent or active tuberculosis, in both HIV positive and HIV negative human subjects. A further object is as the provision of a MTB-C strain suitable for the preparation of the agent. The process for preparing the agent is a further an object of this invention.

## 30 Definitions

"FCMtb" stands for fragments from a *Mycobacterium tuberculosis*-complex (MTB-C) strain

"particle size" refers to, if not otherwise specified, the diameter of the particles. Where the particle size can not be determined exactly, the approximate particle size is meant.

35 "z-average" is the average particle size, determinable as described in the material and methods section.

Abbreviations

	AIDS	Acquired immunodeficiency syndrome
5	BCG	Bacillus Calmette-Guérin
	CFU	Colony-forming unit
	DP	Drug product
	DS	Drug substance
	ELISA	Enzyme-linked immunosorbent assay
10	ELISPOT	Enzyme-linked immunospot assay
	EMA	European Medicines Agency
	FCMtb	Fragments of <i>M. tuberculosis</i> cells
	FIM	First in man
	HIV	human immunodeficiency virus
15	IFN- $\gamma$	Interferon gamma
	IGTIP	Institut per a la Recerca en Ciències de la Salut Germans Trias i Pujol
	IMP	Investigational medicinal product
	IPC	In process controls
	LCS	Liposome concentrate suspension
20	LTBI	Latent tuberculosis infection
	LPS	Lipopolysaccharide
	Mtb	<i>Mycobacterium tuberculosis</i>
	Mtb	<i>Mycobacterium tuberculosis</i> -complex
	NZB	New Zealand Black
25	NZW	New Zealand White
	PPD	Protein-purified derivative
	q.s.	Quantum sufficit
	TB	Tuberculosis
	TST	Tuberculosis skin test
30	WHO	World Health Organization
	w/v	weight/volume
	w/w	weight/weight

Summary of the invention

The invention provides liposome formulations comprising fragments from a *Mycobacterium tuberculosis*-complex (MTB-C) strain (FCMtb) and a liposome forming agent.

5 In a particular embodiment, the z-average size of the particles, as determinable for example by dynamic light scattering, is 120 nm or less, preferably 110 nm or less, more preferably 95 nm or less, and most preferably 80 nm or less. In an alternative embodiment the liposome formulation comprises 1 to 20 % (w/v) sucrose, preferably 2 to 12 % (w/v) sucrose, more preferably 3 to 8 % (w/v) sucrose, and most preferably 4 to 6 % (w/v)  
10 sucrose. It is important to note that, while each of these two embodiments may be fulfilled individually, these embodiments are not to be seen as mutually exclusive and may well occur in combination.

In one particular embodiment the above-described liposome formulation has a z-average  
15 particle size in the range from 40 to 120 nm, preferably from 50 to 110 nm, more preferably from 55 to 95 nm, and most preferably from 55 to 80 nm.

In an alternative particular embodiment the average particle size of the above-described liposome formulation may be smaller, so that the liposome formulation is an emulsion, i.e.  
20 in this particular embodiment the z-average size of the particles is preferably below 40 nm.

In a preferred embodiment of any one or more of the above-described embodiments, the liposome formulation is a liposome formulation, wherein the polydispersity index of the  
25 particles is 0.4 or less, preferably 0.3 or less.

In a more preferred embodiment of any of the above-described embodiments, the *Mycobacterium tuberculosis*-complex (MTB-C) strain is a virulent *Mycobacterium tuberculosis*-complex (MTB-C) strain.  
30

It is further preferred that in any of the embodiments described above, the ratio of (a): the fragments from a *Mycobacterium tuberculosis*-complex (MTB-C) strain and (b) the liposome forming agent, is between 0.01:1 and 1:1, preferably between 0.06:1 and 0.1:1.

35 In a more preferred embodiment of any of the above-described, the liposome formulation additionally comprises: (d) a tensioactive agent. In an even more preferred embodiment, the liposome formulation comprising (d) the tensioactive agent, is a liposome formulation,



wherein the ratio between (a) and (d) is between 0.1:1 and 10:1 (w/w), preferably 0.5:1 and 2:1 (w/w), and most preferably between 0.6:1 and 0.8:1 (w/w).

5 In a particular embodiment of the above-described, the liposome forming agent of the liposome formulation is a phospholipid, preferably lecithin, more preferably one selected from the group consisting of egg lecithin or soy lecithin, and most preferably soy lecithin, each of which may be hydrogenated, partially hydrogenated or non-hydrogenated.

10 In a preferred embodiment of the surfactant-containing liposome formulation, the tensioactive agent is selected from cholate, deoxycholate, cholesterol and cholesterol hemisuccinate.

In a more preferred embodiment, the liposome formulation described above is a liposome formulation, wherein the fragments of MTB-C cells are or comprise cell wall fragments.

15

In another more preferred embodiment, the liposome formulation described above comprises fragments of the MTB-C strain NCTC 13536, which was deposited in 2010 at the NCTC in London. This strain is synonymously called 511, so that the names NCTC 13536 and 511 can be used interchangeably.

20

In an even more preferred embodiment, the liposome formulation described above comprises at least two, preferably three, more preferably four, most preferably all of the following:

- 25 (i) a first polypeptide having a molecular weight of about 70 kDa, similar to a mass fingerprint of *M. tuberculosis* HSP70 protein (Rv0350),
- (ii) a second polypeptide having a molecular weight of about 38 kDa, similar to a mass fingerprint of *M. tuberculosis* 38 kDa protein (Rv 0934),
- (iii) a third polypeptide having a molecular weight of about 30 kDa, similar to a mass fingerprint of *M. tuberculosis* Ag85B protein (Rv 1866c), and
- 30 (iv) a fourth polypeptide having a molecular weight of about 10 kDa, similar to a mass fingerprint of *M. tuberculosis* CFP10 protein (Rv3874), and
- (v) a fifth polypeptide having a molecular weight of about 6 kDa, similar to a mass fingerprint of *M. tuberculosis* ESAT-6 protein (Rv3875).

35

In a yet more preferred embodiment, the liposome formulation comprises a lipopolypeptide having a molecular weight of about 19 kDa, similar to a mass fingerprint of *M tuberculosis* 19 kDa lipoprotein antigen precursor LpqH (Rv 3763).

- 5 Even more preferably, the liposome formulation described above is further characterized in that at least one of the following antigens of *Mycobacterium tuberculosis*, or fragment thereof, is present: HSP70, 38 kDa protein and Ag85B. Fragment in this sense is any part, such as for example a degradation product, of any of these polypeptides.
- 10 In a more preferred embodiment, the liposome formulation described above contains lipids which are typically found in *Mycobacterium tuberculosis* or derivatives thereof, such as conjugation products like sugar conjugated lipids. It is further preferred that one or more of mycolic acids, preferably belonging to any one or more of types I, III or IV, is comprised. Alternatively or in addition, a sugar-conjugated mycolate, preferably trehalose
- 15 dimycolate may be comprised in the formulation. Alternatively or in addition, it is further preferred, that at least one MTB-C-derived glycolipid is present in the liposome formulation according to the present invention, and a preferred glycolipid is liporabinomannan.
- 20 The liposome formulation described above may additionally comprise one or more surfactants, which is/are preferably from the group of non-ionic surfactants.

In a further preferred embodiment the liposome formulation according to any of the preceding claims additionally comprises one or more salts or solution thereof, whereby

25 the preferred salt is sodium chloride.

In an even more preferred embodiment of any of the above the liposome formulation of this invention is freeze-dried.

- 30 The invention also provides a suspension, wherein the liposome formulation of any of the preceding claims is reconstituted in a solvent. In a preferred embodiment, the solvent of this suspension is aqueous, and preferably is or comprises physiological serum.

The invention also provides a pharmaceutical composition comprising the liposome

35 formulation as described in any one or more of the embodiments above, or the suspension as described in any one or more of the embodiments described above, and a pharmaceutically acceptable carrier or diluent or excipient, whereby any substance

suitable as carrier, diluent or excipient may be used. In a preferred embodiment thereof, this pharmaceutical composition additionally comprises a pharmaceutically acceptable adjuvant.

5 The invention also provides a product for use in a method of treatment of the human or animal body by therapy. That is, it provides the liposome formulation according to any one or more of the embodiments described above, the suspension according to any one or more of the embodiments described above, or the pharmaceutical composition according to any one or more of the embodiments described above, for use in a method of treatment  
10 of the human or animal body by therapy. In a particular embodiment, the invention provides this liposome formulation, suspension or pharmaceutical composition for injection. In another particular embodiment, the invention provides this liposome formulation, suspension or pharmaceutical composition for use in a method of treating or preventing tuberculosis. These particular embodiments may be met individually or in  
15 combination.

In a more particular embodiment, the invention provides the liposome formulation, suspension or pharmaceutical composition according to what is described above in relation to the use thereof in a method of treatment of the human body by therapy, further  
20 characterized in that it is for administration to the human body in a dose comprising 1 to 1000, preferably 3 to 250, more preferably 4 to 80, and most preferably about 5, about 25 or about 50 µg/dose FCMtb.

In three more particular embodiments (a) to (c), the liposome formulation, suspension or  
25 pharmaceutical composition according to what is described above in relation to the use thereof in a method of treatment of the human or animal body by therapy is (a) for use in a method of prevention of active tuberculosis in individuals with a latent tuberculosis infection, (b) for use in a method of primary prophylaxis of tuberculosis in order to prevent infection of individuals who had been exposed to the disease, but are not yet infected, or  
30 (c) for use in a method of treating or preventing latent tuberculosis.

In a preferred embodiment of the above liposome formulation, suspension or pharmaceutical composition for the use thereof in a method of treatment of the human or animal body by therapy is its use in combination therapy or adjunctive therapy. Adjunctive  
35 therapy is an additional or secondary therapy combined with a primary treatment that increases effectiveness in treating a condition. A particular embodiment of combination therapy is one wherein the combination therapy comprises an antibiotic, preferably one

ore more of isoniazide and an ansamycine, whereby the ansamycine is most preferably rifampicin. In a particular embodiment of the present invention, adjunctive therapy is administered to a HIV positive human subject, and a single dose of 25 µg FCMtb is preferred.

5 The invention also provides a process for preparing any of the agents, that is the liposome formulation, the suspension or the pharmaceutical composition.

The invention further provides the MTB-C strain NCTC 13536, deposited in 2010 at the NCTC in London.

10

#### Detailed description of the invention

The invention provides liposome formulations comprising fragments from a *Mycobacterium tuberculosis*-complex (MTB-C) strain (FCMtb) and a liposome forming agent.

15

Unless expressly specified otherwise, the term "comprising" is used in the context of the present application to indicate that further members may optionally be present in addition to the members of the list introduced by "comprising". It is, however, contemplated as a specific embodiment of the present invention that the term "comprising" encompasses the possibility of no further members being present, i.e. for the purpose of this embodiment "comprising" is to be understood as having the meaning of "consisting of".

20

The detailed description discloses specific and/or preferred variants of the individual features of the invention. The present invention also contemplates as particularly preferred embodiments those embodiments, which are generated by combining two or more of the specific and/or preferred variants described for two or more of the features of the present invention.

25

It is generally accepted that a liposomation process generates a lipidic environment, facilitating the solubility and leading to a suspension of substances, such FCMtb. Liposomes within the meaning of this invention may be unilamellar, multilammellar or combinations thereof.

30

FCMtb can be of any type of substance derived from the MTB-C strain, whereby fragments derived from proteins and/or lipids are preferred. FCMtb within the sense of this application is typically a mixture of different protein antigens and lipids from MTB-C cells.

35

The cell fragments may be obtained by any method known to the person skilled in the art suitable for fragmenting microbial or bacterial cells, such as specifically MTB-C cells, for example homogenisation. The homogenisation can be carried out by means of ultrasound sonication, or by means of the use of small beads of approximately 0,1 mm in diameter, for example, silica or zirconia/silica beads, together with a mechanical homogenizer. A mechanical homogenizer that can be used, for example, is the BioSpec BeadBeater® model. The MTB-C cells are broken by means of this homogenisation process, so that small cell fragments, typically including small cell wall fragments, are obtained. A typically relevant feature of the manufacturing of the cell fragments is the "detoxification" of the cell wall fragments by delipidation, well known to the person skilled in the art, a process that allows removing the endotoxin-like molecules. The FCMtb is therefore preferably detoxified and pasteurized, the obtained liposome formulation is then sterile and free of endotoxins. The dispersion of cell fragments in buffer can optionally be lyophilised to facilitate the storage thereof. To that end, the dispersion can be distributed into vials and lyophilised at a temperature between -15 °C and -120 °C, such as for example -45 °C and with a vacuum, such as between 0.1 and 0.5 mbar.

The liposomes according to this invention usually have a size distribution in which at least 99.9% (by number) are smaller than 1 µm. In a particular embodiment, the z-average size of the particles, as determinable by dynamic light scattering, is 120 nm or less, preferably 110 nm or less, more preferably 95 nm or less, and most preferably 80 nm or less. In dynamic light scattering the z-average parameter is considered a stable and important number obtainable by the technique, and the size number that is preferably used for quality control purposes. Preferably, the liposomes of the formulation according to this invention are monomodal, i.e. they show only one peak in dynamic light scattering measurements. More preferably, the liposomes of the formulation according to this invention are spherical, as can be tested by electron microscopy of freeze-fracturing preparations of the liposome formulation, as shown in Example 9. Spherical thereby means that for at least 90 % of the liposome particles (by number), all surface points of the individual particle have similar or identical distance to the center of the liposome, i.e. the minimal radius of such a particle relates to the maximal radius of the same particle in a ration of 0.6 or more, 0.7 or more, 0.8 or more or 0.9 or more. The liposome formulation according to the present invention can comprise multilamellar or unilamellar liposomes, or a mixture thereof. In line with standard knowledge of the person skilled in the art, the dynamic light scattering measurements should be performed in a suitable buffer, i.e. a buffer which does not by itself cause disruption, disintegration or fusion of the liposomes or significantly destabilize them physically in any other way. As a rule of thumb, any buffer

may be suitable as long as both ionic strength and pH value are comparable to the buffer in which the liposomes had been formed may be suitable. Preferably, a buffer of similar or identical composition to the buffer in which the liposomes had been formed, is used.

- 5 In an alternative embodiment, the liposome formulation additionally comprises 1 to 20 % (w/v) sucrose, preferably 2 to 12 % (w/v) sucrose, more preferably 3 to 8 % (w/v) sucrose, and most preferably 4 to 6 % (w/v) sucrose. Approximately 5 % sucrose are particularly preferred.
- 10 It is important to note that, while each of these embodiments relating, the one relating to a particular particle size and the other relating to the presence of sucrose, may be fulfilled individually, these embodiments are not to be seen as mutually exclusive and may well occur in combination.
- 15 In one particular embodiment, the above-described liposome formulation has a z-average particle size in the range from 40 to 120 nm, preferably from 50 to 100 nm, and more preferably from 55 to 95 nm, and more preferably from 55 to 80 nm. The z-average particle size is thereby preferably measured by dynamic light scattering, as described in general above and in detail in the section "Materials and methods"
- 20 In an alternative particular embodiment, the z-average particle size of the above-described liposome formulation may be smaller, so that the liposome formulation is an emulsion, i.e. in this particular embodiment the z-average size of the particles is preferably below 40 nm.
- 25 In a preferred embodiment of any one or more of the above-described embodiments, the liposomes of the formulation according to this invention are furthermore monodisperse, which means that no significant width of the size distribution is observed. This is technically tested by a low polydispersity index (PDI) as determined by dynamic light
- 30 scattering, such as 0.4 or less, preferably 0.3 or less. Hence, the liposome formulation is a liposome formulation, wherein the polydispersity index of the particles as determinable by dynamic light scattering is 0.4 or less, preferably 0.3 or less, and most preferably 0.25 or less.
- 35 The fragments from the *Mycobacterium tuberculosis*-complex (MTB-C) strain are obtainable by a process comprising an upstream process and a downstream process. For

illustrative purposes, the five main steps are briefly described here and particular modes of carrying out the process are given in Examples 2 and 3 below.

Upstream process (Example 2):

- 5 Step 1: Culture of *Mycobacterium tuberculosis*  
Step 2: Harvest of *Mycobacterium tuberculosis* and freezing of crude extract

Downstream process (Example 3):

- Step 3: Cell fragmentation and delipidation  
10 Step 4: Pasteurization  
Step 5: Freeze-drying (optional)

In a more preferred embodiment of any of the above-described embodiments, the *Mycobacterium tuberculosis*-complex (MTB-C) strain is a virulent *Mycobacterium*  
15 *tuberculosis*-complex (MTB-C) strain. Virulent refers to the pathogenicity by case and/or the ability of the bacilli to invade the tissues of the host. The virulent strain can be any virulent strain of any of the species belonging to MTB-C, but a strain belonging to *M. tuberculosis* is preferred. The MTB-C strain according to this invention may be cultivated by inoculation in culture media well-known by the person skilled in the art, for example  
20 Middlebrook 7H10 or 7H11 agar, Sauton's medium or Proskauer-Beck medium. The culture of the virulent strain is preferably performed over an extended time period, such as, for example, a period equal to or greater than three weeks, preferably comprised between 3 and 4 weeks. The temperature of the culture is preferably maintained between 34 °C and 38 °C. Once the culture ends, the cells are harvested and isolated using  
25 techniques well known in the art, such as those described in patent application ES2231037-A1.

The liposome agent of the liposome formulation is preferably a hydrogenated, partially hydrogenated or non-hydrogenated phospholipid. The phospholipid used can be or  
30 comprise, for example: phosphatidylcholine, phosphatidylserine and phosphatidyl-inositol. Most typical is phosphatidylcholine, which can be synthesized or isolated from a variety of natural sources. Preferably the liposome forming agent is or comprises lecithin, selected from the group consisting of egg lecithin and soy lecithin. Soy lecithin is a complex mixture of phospholipids including inter alia phosphatidylcholine, and is particularly preferred.  
35 Typical lipids which may also be comprised in the formulation, either as liposome forming agent itself, or as further component, are: dicetyl phosphate (DCP), dimyristoyl phosphatidylcholine (DMPC), dimyristoyl phosphatidylglycerol (DMPG), dioleoyl

phosphatidylcholine (DOPc), dioleoyl phosphatidylethanolamine (DOPE), dioleoyl phosphatidylserine (DOPS), dipalmitoyl phosphatidylcholine (DPPC), dipalmitoyl phosphatidylglycerol (DPPG), phosphatidylcholine (PC) and/or phosphatidylserine (PS), whereby the respective lipid may be hydrogenated, partially hydrogenated or non-  
5 hydrogenated. The liposomes can be formed using conventional auxiliary lipids and techniques well-known by the person skilled in the art, such as those described in the patent application ES2231037-A1.

It is further preferred that in any of the embodiments described above, the ratio of (a): the  
10 fragments from a *Mycobacterium tuberculosis*-complex (MTB-C) strain and (b) the liposome forming agent, is between 0.01:1 and 1:1, preferably between 0.06:1 and 0.1:1. In a more preferred embodiment of any of the above-described, the liposome formulation additionally comprises: (d) a tensioactive agent. Generally, all types of agents capable of  
15 changing the value of surface tension may be used as tensioactive agent in the sense of this invention, but excluded are compounds which fall under the definition of the liposome-forming agent given above. Various types of tensioactive agents are known to the person skilled in the art and may be used in the liposome formulation according to the present invention. As is known to the skilled person, tensioactive agents are generally chemicals  
20 with a polar-nonpolar structure. Without wishing to be limited to any particular theory, tensioactive agents generally have the tendency to locate to the surface of particles, thereby creating a monomolecular layer on the interface that reduces the surface tension value. Tensioactive agents are also referred to as surfactants or active surface agents. In a preferred embodiment of the surfactant-containing liposome formulation, the  
25 tensioactive agent is selected from sterols and derivatives thereof, such as cholesterol, and/or bile salts or derivatives thereof, such as cholate. Particularly preferred embodiments are those wherein the tensioactive agent is selected from cholate, deoxycholate, cholesterol and cholesterol hemisuccinate. A good, but not limiting mode of carrying out the invention is where the liposomes of the formulation comprise both soy-derived lecithin and sodium cholate.

30

In an even more preferred embodiment, the liposome formulation comprising (d) the tensioactive agent, is a liposome formulation, wherein the ratio between (a) and (d) is between 0.05:1 and 3:5 (w/w). Various types of liposome forming agents may be used, as are well known to the person skilled in the art.

35

The liposomes can optionally contain additives improving their stability, for example: vitamin E, which is believed to act as a lipid antioxidant.



In a more preferred embodiment, the liposome formulation described above is a liposome formulation, wherein the fragments of MTB-C cells are or comprise cell wall fragments.

5

Any strain belonging to MTBC, and preferably any strain belonging to *Mycobacterium tuberculosis*, may be used. In another more preferred embodiment, the liposome formulation described above comprises fragments of the MTB-C strain NCTC 13536, which was deposited in 2010 at the NCTC in London (Example 1). Another strain which  
10 may be used, and fragments of which may therefore be comprised in the liposome formulation, is called H37Rv, which, for example, can be obtained from the National Collection of Type Cultures (NCTC), London, Great Britain (deposit number NC007416) and is often used by researchers in this field. It is also possible that more than one strain be used, i.e. that the liposome formulation comprises fragments of various, such as two,  
15 three, or more than three strains.

Considering the approximately 4000 putative antigens of *M. tuberculosis*, it is impossible to analyse drug substance for all of these proteins. Nevertheless, certain MTB-C proteins have been shown to be relevant for the desired immune response. These are five protein  
20 bands have approximate sizes of 6, 10, 30, 38, and 70 kDa (Renshaw, et al., 2005, *EMBO Journal* 24, 2491-2498; Singh, et al., 2005, *Clin. Diagn. Lab. Immunol.* 12(2), 354-358). Therefore, in an even more preferred embodiment, the liposome formulation described above comprises at least two, preferably three, more preferably four, and most preferably all of the following:

25

- (i) a first polypeptide having a molecular weight of about 70 kDa as measured following electrophoresis on a sodium dodecylsulfate (SDS) polyacrylamide gel, wherein the first polypeptide has a mass fingerprint similar to a mass fingerprint of *M. tuberculosis* HSP70 protein (Rv0350),
- 30 (ii) a second polypeptide having a molecular weight of about 38 kDa as measured following electrophoresis on a sodium dodecylsulfate (SDS) polyacrylamide gel, wherein the second polypeptide has a mass fingerprint similar to a mass fingerprint of *M. tuberculosis* 38 kDa protein (Rv 0934),
- (iii) a third polypeptide having a molecular weight of about 30 kDa as measured  
35 following electrophoresis on a sodium dodecylsulfate (SDS) polyacrylamide gel, wherein the third polypeptide has a mass fingerprint similar to a mass fingerprint of *M. tuberculosis* Ag85B protein (Rv 1866c), and

- (iv) a fourth polypeptide having a molecular weight of about 10 kDa as measured following electrophoresis on a sodium dodecylsulfate (SDS) polyacrylamide gel, wherein the fourth polypeptide has a mass fingerprint similar to a mass fingerprint of *M. tuberculosis* CFP10 protein (Rv3874),  
5 and
- (v) a fifth polypeptide having a molecular weight of about 6 kDa as measured following electrophoresis on a sodium dodecylsulfate (SDS) polyacrylamide gel, wherein the fifth polypeptide has a mass fingerprint similar to a mass fingerprint of *M. tuberculosis* ESAT-6 protein (Rv3875).

10

In a yet more preferred embodiment thereof, the liposome formulation further comprises a lipopolypeptide having a molecular weight of about 19 kDa as measured following electrophoresis on a sodium dodecylsulfate (SDS) polyacrylamide gel, wherein the lipopolypeptide has a mass fingerprint similar to a mass fingerprint of *M. tuberculosis* 19  
15 kDa lipoprotein antigen precursor LpqH (Rv 3763). The respective band can be visualized by methods known in the art, such as silver staining. The researchers of the present invention surprisingly found that this polypeptide induces a high total IgG humoral response, which may be the highest humoral response among all antigens in the formulation.

20

Examples of how the polypeptides or lipopolypeptides may be identified are given in Example 4.

Even more preferably, the liposome formulation described above is further characterized  
25 in that at least one of the following antigens of *Mycobacterium tuberculosis*, or fragment thereof, is present: HSP70, 38 kDa protein, Ag85B, and most preferably at least one of HSP70, 38 kDa protein and Ag85B. Fragment in this sense is any part, such as for example a degradation product, of any of these polypeptides. Various ways of obtaining such fragments are possible, for example chemical or enzymatic hydrolysis, whereby it is  
30 not relevant if the fragmentation had occurred purposely or not, prior to liposome formation or thereafter. It is preferred that the respective fragment can be assigned to its respective origin, such as, for example, by substantial overlap in amino acid sequence, such as at least 5, at least 10, at least 20 consecutive amino acids.

35

The fragments according to the present invention are preferably obtained from bacilli grown under the stressful conditions of starvation, low oxygen and low pH. Low oxygen is due to the growth of the bacteria on plates which are closed in hermetic bags during the

growth period, which is for example 21 days, which leads to a microaerobiotic environment. The low pH is explained as follows: At the beginning of culture the pH value is 7,0 - 6,8, and the end, after typically 21 day of culture, the pH value is 6,4 - 6,5). Under these conditions, the metabolism of the bacteria is slower, which leads to stationary growth. It is understood that this renders the bacilli more resistant to stress. Under such conditions cultured bacilli develop similar characteristics as *in vivo* latent bacilli in LTBI (Latent tuberculosis infection). The antigens present in FCMtb are thus expected to trigger a new immunological response against antigens of the latent bacilli, i.e. the so-called "structural" antigens as well as those associated to stress responses.

Mycobacterial glycolipids have long been recognized to have immunomodulatory activity, notably the induction of granulomatous responses and to exert potent adjuvant-like effects. Therefore, in a more preferred embodiment, the liposome formulation described above contains lipids which are typically found in *Mycobacterium tuberculosis*, or derivatives thereof, such as conjugation products like sugar conjugated lipids. Several immunogenic lipid components have been identified in *M. tuberculosis* samples (Brennan, Tuberculosis (Edinburgh), 2003, 83(1-3), 91-97) and analytical methods for their determination have been developed (electrophoresis, SDS-PAGE, thin layer chromatography). Although the isolation of each lipid component would require such an aggressive treatment that quantitative data or percentages of each component detectable in the MTB-C extract or in the liposome formulation are difficult to obtain, the qualitative characterisation shall serve to characterize a further preferred embodiment of this invention. According to this further preferred embodiment, one or more of mycolic acids, preferably belonging to any one or more of types I, III or IV is comprised. Alternatively or in addition, a sugar-conjugated mycolate, preferably trehalose dimycolate may be comprised in the formulation. Alternatively or in addition, a glycolipid lipoarabinomannan (LAM) may be comprised in the formulation. Furthermore the multiantigenic nature of the fragments (multiantigenic protein mixture plus lipids, instead of purified antigens alone) is believed to be an advantage and therefore the cell fragmentation process can be adapted by the skilled person so as to allow the optimal cellular antigen mixture.

Homogenisation of the MTB-C cells is carried out in the presence of one or more surfactants, preferably a nonionic surfactant. Hence, the liposome formulation described above may additionally comprise one or more such surfactants. A large number of such surfactants are within the standard knowledge of a person skilled in the art. Preferably, the nonionic surfactant used is selected from the group consisting of alkylphenol ethoxylates, and sorbitan ester ethoxylates. More preferably, the nonionic surfactant is selected from

the group of octylphenol ethoxylates. Even more preferably, octylphenol ethoxylates with an ethylene oxide content comprised between 7 and 8 moles are used, which surfactants can be found on the market under the name Triton X-114®. The homogenised mass containing the cell wall fragments is subjected to a conventional treatment to separate and reject the non-fragmented cells and the solubilized components. Centrifugation at different speeds and washing with buffer solution as described in patent application ES2231037-A1 can be used for example. Sediment containing the cell wall fragments is obtained after performing the mentioned purification processes. Said sediment is dispersed in phosphate-buffered saline (PBS) buffer and is subjected to a conventional treatment to ensure the complete inactivation of the MTB-C cells which may have remained viable after the fragmentation and purification process. The mentioned treatment can be a chemical process, for example by means of treatment with formaldehyde, or a physical process, for example by means of autoclaving or pasteurisation treatment. Examples of lipid characterization are given in Example 5 below.

In a further preferred embodiment, the above described liposome formulation additionally comprises one or more salts or solution(s) thereof, whereby the preferred salt is sodium chloride.

In an even more preferred embodiment of any of the above, the liposome formulation is freeze-dried. The liposomes can be subjected to lyophilisation to thus obtain the immunotherapeutic agent in the form of lyophilised liposomes. To that end, the dispersion can be distributed into vials and lyophilised at a low temperature, such as between -15 °C and -120 °C, such as for example -45 °C and with a vacuum, such as between 0.1 and 0.5 mbar. The vials obtained after lyophilisation contain the liposome formulation suitable as immunotherapeutic agent and they are preferably stored at very low temperatures, for example at -70 °C.

The invention also provides a suspension, wherein the liposome formulation of any of the preceding claims is reconstituted in a solvent. In a preferred embodiment, the solvent of this suspension is aqueous, more preferably and most preferably is or comprises physiological serum. Methods of suspending liposome formulations in a solvent are well known to the person skilled in the art. It is a particularly advantageous property of the formulation according to this invention that it can be suspended faster than conventional liposome formulations comprising MTB-C fragments (see Example 9)

One object of the invention is the provision of an agent comprising cell wall fragments of a strain of MTB-C for the preparation of a pharmaceutical composition, whereby the agent is or comprises the liposome formulation described above in any of the embodiments described or combinations thereof. The main scope of the pharmaceutical formulation/galenic formulation of the drug substance is to obtain a suspension effective and stable enough to be well recognized by the cells and which has the potential to trigger a relevant cellular immune response in a human or animal body. To that end, the invention also provides a pharmaceutical composition comprising the liposome formulation, or the suspension as described in any one or more of the embodiments described above, and a pharmaceutically acceptable carrier, excipient or diluent. Various such carriers, excipients and diluents are known to the person skilled in the art, and they are in no way limited by this disclosure. Rather, any substance suitable as carrier, excipient or diluent may be used. In a preferred embodiment, this pharmaceutical composition additionally comprises a pharmaceutically acceptable adjuvant. Adjuvant is thereby to be understood as a substance comprised in this embodiment of the invention, whereby the adjuvant is a substance capable of stimulating the immune system when applied to a human or animal body in response to the target antigen, whereby the adjuvant does not itself confer immunity. Without wishing to be limited to any particular adjuvant substance, preferred embodiments are wherein the adjuvant is an aluminium salt, such as aluminium chloride, or a mineral oil or a composition comprising mineral oil, such as incomplete Freund's adjuvant (IFA) or complete Freund's adjuvant (CFA), or an ammonium halogenide, such as an alkylated ammonium bromide, such as dimethyldioctadecyl-ammonium bromide.

The invention also provides a product for use in a method of treatment of the human or animal body by therapy. That is, it provides the liposome formulation according to any one or more of the embodiments described above, the suspension according to any one or more of the embodiments described above, or the pharmaceutical composition according to any one or more of the embodiments described above for use in a method of treatment of the human or animal body by therapy.

The drug can be administered in a mucosa, for example, ocular, intranasal, oral, gastric, intestinal, vaginal, or urinary tract mucosa, or parenterally, for example, subcutaneously, intradermally, intramuscularly, intravenously, or intraperitoneally. Parenteral administration is preferred. In a particular embodiment, the invention provides this liposome formulation, suspension or pharmaceutical composition for injection.

In another particular embodiment, the invention provides this liposome formulation, suspension or pharmaceutical composition for use in a method of treating or preventing tuberculosis. These particular embodiments may be met individually or in combination. The inventors of the present study have found that the formulation according to the present invention leads to increased cellular immune response and also controls the process of constant re-infection that may otherwise occur in latent tuberculosis infection, by boosting the immunity against growing bacilli and by inducing immunity against the non-replicating bacilli.

The suitable dose of the liposome formulation, suspension or pharmaceutical composition according to what is described above in relation to the use thereof in a method of treatment of the human body by therapy depends on several parameters, including the method of administration and the subject to be treated. In a preferred embodiment, it is for administration to the human body. In a preferred embodiment thereof, this occurs in a dose comprising 1 to 1000, preferably 3 to 250, more preferably 4 to 80, and most preferably about 5, about 25 or about 50  $\mu\text{g}/\text{dose}$  FCMtb. A dose of 25  $\mu\text{g}$  is particularly preferred.

In three more particular embodiments (a) to (c), the liposome formulation, suspension or pharmaceutical composition according to what is described above in relation to the use thereof in a method of treatment of the human or animal body by therapy is (a) for use in a method of prevention of active tuberculosis in individuals with a latent tuberculosis infection. In an alternative more particular embodiment, (b) for use in a method of primary prophylaxis of tuberculosis in order to prevent infection of individuals who had been exposed to the disease, but are not yet infected or (c) for use in a method of treating or preventing latent tuberculosis.

The liposome formulation, suspension or pharmaceutical composition for the use thereof in a method of treatment of the human or animal body by therapy can be administered in the form of a single dose or of several, such as two, three, four, five or more than five, doses, by means of the repetition at certain time intervals. Preferably two doses are administered separated by a period comprised between 2 and 5 weeks, preferably between 3 and 4 weeks.

Examples 8, 10 and 12 are examples of how the liposome formulation according to this invention may be applied to human or animal subjects.

A preferred embodiment of the substance above is the liposome formulation, suspension or pharmaceutical composition for use in combination or adjunctive therapy. Medical practitioners use adjunctive therapy frequently to get better cure rates or a faster response to primary treatment. A combination therapy or adjunctive therapy involves using more than one medicine to treat the human or animal body by therapy. A first particular embodiment of a combination therapy is one wherein the combination therapy comprises an antibiotic, preferably one or more of isoniazide and an ansamycine, whereby the ansamycine is most preferably rifampicin. A second particular embodiment thereof is where the combination therapy comprises other prophylactic vaccines against tuberculosis, such as those mentioned in S.H.E. Kaufmann, Nature Rev. Immunol., 2006, 6, pages 699-704, such as for example the Bacillus Calmette-Guerin (BCG) vaccine, subunit vaccines or recombinant BCG vaccines. The first and second particular embodiment may be combined.

In combination therapy or adjunctive therapy, administration of these two (or more) substances can be simultaneous, or it can be done in two (ore more) inoculations separated over time. The period between the inoculations can even be several years long. In the case of a combination therapy, inoculations separated over time, first a prophylactic vaccine against tuberculosis is preferably administered, and the drug comprising the cell wall fragments of a virulent strain of MTB-C, which acts as a re-stimulating (boost) agent of the initially inoculated vaccine, is subsequently administered. In one embodiment, only a single dose is administered to the human subject, and this dose is preferably 25 µg FCMtb.

Alternatively, several different treatment strategies or types of care are employed simultaneously in adjunctive therapy. In a particular embodiment of the present invention, adjunct therapy is administered to a human subject with an impaired immune system, such as an individual suffering from HIV, or any individual otherwise prone to tuberculosis infection and/or in need of such therapy. Isoniazid may also be administered in the adjunctive therapy. Further, the adjunctive therapy may comprise administration of any drug or combination of drugs to treat the impaired immune system, such as to treat the HIV infection. Typical drugs to treat HIV infections are antiretroviral drugs, and a non-limiting overview can be found in: "Antiretroviral therapy for HIV infection in adults and adolescents

Recommendations for a public health approach: 2010 revision",  
Authors: World Health Organization, ISBN: 9789241599764.

Thus, the present inventors have provided a solution for the need of providing effective tuberculosis protection, such as vaccination, to HIV positive human subjects.

5 Whether an individual is to be considered HIV positive or not (i.e. HIV negative) can be tested by any test which allows detection of the presence of the human immunodeficiency virus (HIV), the virus that causes acquired immunodeficiency syndrome (AIDS), in a body fluid from the individual to be tested, wherein the body fluid is typically any one selected from serum, saliva, or urine. Such tests may detect antibodies, antigens, or RNA. An overview of suitable screening test is given in Chou *et al.*, *Ann. Intern. Med.* 2005 Jul 10 5;143(1):55-73.

The inventors of the present invention have surprisingly found that a single dose of 25 µg FCMtb administered to a HIV positive human subject provides a strong response.

15 A single dose of 25 µg FCMtb was also powerful when administered to a HIV negative human subject. The present inventors showed that this is particularly useful in subjects suffering from latent tuberculosis (Example 12). Thus, a single dose of 25 µg FCMtb to be administered to a HIV positive or a HIV negative individual is a preferred embodiment of the invention.

20

The invention also provides a method of manufacture, characterized in that it is suitable for obtaining a liposome formulation according to any one or more of the embodiments described above, as well as of a suspension, or pharmaceutical composition comprising the same. One non-limiting Example thereof is given as Example 11 below.

25

The invention further provides the MTB-C strain NCTC 13536, deposited in 2010 at the NCTC in London. The strain has a low genetic polymorphism. Therefore, formulations comprising fragments of NCTC 13536 have the advantage of very high reproducibility because of the low genetic polymorphism.



Preferred mode of carrying out the invention

It is preferred that specific doses of 50 µg FCMtb/dose, or 25 µg FCMtb /dose or 5 µg FCMtb/dose are used. For example, when the dose is 50 µg FCMtb, the amounts/substances given in Table 1 are present in one vial of the formulation:

COMPONENTS	UNIT PER VIAL	FUNCTION
<b>DRUG SUBSTANCE</b>		
FCMtb	66.7 µg	Immunogen
<b>Further components</b>		
Sucrose	20,000.0 µg	Charge substance (freeze-drying) and cryoprotector
Soy lecithin <sup>1</sup>	845.8 µg	Liposome forming agent
Sodium cholate	92.0 µg	Tensoactive
Sodium chloride <sup>2</sup>	20.8 µg	Solvent
<b>Particle characterization</b>		
z-average particle size	75 +/- 20 nm	
Polydispersity index	≤ 0.350	

<sup>1</sup> Containing Phosphatidylcholine (94.0% (w/w))

<sup>2</sup> Added as NaCl 0.9% solution.

**Table 1.**

10

For 25 µg/dose or 5 µg/dose application, other vials are prepared, wherein all number values shown in Table 1 –except sucrose - are to be divided by the factor of 2 or 10, respectively. The content of sucrose in the formulations (50 µg, 25 µg and 5 µg) is always 20.000 µg unit/vial.

15

A liposome formulation made of soy lecithin (liposome forming agent) highly enriched with phosphatidylcholine (94.0% (w/w)) and sodium cholate (tensoactive agent) has shown to be adequate to guarantee greater solubility of the drug substance during manufacture as well as in the reconstituted suspension. One important parameter for stability of the FCMtb in the liposome formulation is the proportion of the components which constitute the liposome. After testing different ratios of FCMtb/lipid component, it was established that a very good ratio is approximately 0.03:0.2:0.7 (FCMtb:sodium cholate:soy lecithin, w/w/w). It was further observed that the liposome formation was enhanced by the

20

presence of salts in the aqueous phase. Therefore, sodium chloride is included in this particular formulation.

Parameter		Acceptance criteria	Test methods
<i>Appearance</i>		White to off-white powder	Visual inspection
<i>Cake morphology</i>		Flat to almost flat and homogeneous	Visual inspection
<i>Dosage uniformity</i>	<i>Mass uniformity (mg/vial)</i>	21.02 ± 15%	Weighing, in house method
	<i>Mass mean (mg/vial)</i>	Mass ± 5%	Weighing, in house method
<i>Water content (%)</i>		≤ 3 %	Karl Fischer coulometric assay, Ph.Eur.2.5.12 (USP<921>)
<i>Total protein content of FCMtb</i>		90-140 µg /mg FCMtb	BCA assay, Ph. Eur. 2.5.33 (USP <1057>)
<i>Time to reconstitution (s)</i>		Well reconstituted ≤10s	Visual inspection
<i>pH</i>		7-8	Potentiometry, Ph.Eur 2.2.3 (USP<791>)
<i>Particle size</i>	<i>z-average (nm) (Polydispersity index<sup>1</sup>)</i>	75 ± 20 (≤ 0.310)	Dynamic light scattering Ph.Eur. 2.9.31
<i>Immunogenic potency in M. Tuberculosis infected murine model</i>	<i>Antigen-specific IFN-γ Spot forming units</i>	PPD 3-12 Ratio SFU/10 <sup>6</sup> cells with respect to basal value (Basal value in SFU/10 <sup>6</sup> cells)	ELISpot
<i>Protein profile</i>	<i>SDS-PAGE</i>	Positive for bands: 70, 38, 30, 10, 6 kDa	Electrophoresis by SDS-PAGE
	<i>Western-blot</i>	Positive for HSP70 (Rv0350), 38 kDa (Rv0934), Ag85B (Rv1886c)	Western-blot
<i>Sterility</i>		Sterile	Ph. Eur. 2.6.1 (USP<71>)
<i>Bacterial endotoxins (IU/dose)</i>		≤ 10 IU/ vial	Ph. Eur. 2.6.14 method D (USP<85>)

**Table 2:** Drug product (FCMtb), measured after reconstitution of the lyophilized liposome composition

5

In a preferred mode the invention is carried out such that the liposome formulation according to this invention has the properties according to Table 2.

For administration to living subjects, the vial can be reconstituted with 0.4 ml of water for injections to give a suspension containing 166.7 µg /ml of FCMtb.

Table 3 shows the concentration of each component per vial after reconstitution at 50µg/dose. For 25 µg/dose or 5 µg/dose application, other vials are used, so that in line with what is said above about Table 1, all number values shown in Table 3 – except sucrose - are to be divided by the factor of 2 or 10, respectively. The content of sucrose in the formulations (50 µg, 25 µg and 5 µg) is always 50.000 ug/mL

Components	Concentration per mL
<b>DRUG SUBSTANCE</b>	
FCMtb	166.7 µg/mL
<b>EXCIPIENTS</b>	
Sucrose	50,000.0 µg/mL
Soy lecithin	2,114.4 µg /mL
Sodium cholate	230.0 µg /mL
Sodium chloride	52.1 µg /mL

10 **Table 3** Concentration of components after reconstitution in 0.4 mL water for injection

#### Materials and methods

#### Reference materials

15

- a) Monoclonal antibodies: Specific monoclonal antibodies (anti-HSP70, anti-38kDa, anti-Ag85B, (from Lionex Diagnostic GmbH, Braunschweig, Germany)) are used for the identification of the protein profile of FCMtb batches.
- b) Albumin Standard: This standard, used for the determination of protein content, is composed of bovine albumin in 0.9% of saline solution (2 mg/ml), conserved in sodium azide (manufacturer: Pierce).
- 20 c) Trehalose 6,6'-dimicolate from *Mycobacterium tuberculosis* (TDM) standard: Commercially available TDM (Sigma) is used for the identification of TDM of FCMtb batches.
- 25 d) Mycolic acids from *Mycobacterium tuberculosis* standard  
A commercially available mycolic acid (Sigma) is used for the identification of mycolic acid of FCMtb batches.
- e) Molecular weight marker: A commercially available molecular weight marker named SeeBlue® Plus pre-stained Standard™ (Invitrogen) is used.

Determination of parameters

a) pH

5 The pH of the reconstituted suspension of FCMtb (20mg/ml) is determined by potentiometry according to Ph. Eur. 2.2.3 and USP<791>.

b) Water content

10 The test for the determination of residual water of the lyophilized FCMtb is carried out using Coulometric Karl Fisher equipment, and it follows the general indications of the Ph. Eur., method 2.5.12, and USP <921> *Water determination*.

c) Determination of total protein content

15 The test for the determination of total protein content of the FCMtb is carried out using a commercial kit (BCA kit, Pierce) and following Ph.Eur., method 2.5.33, method 4 (Bicinchoninic acid or BCA assay) and USP <1057>.

d) Identification of protein profile by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)

20 The test is performed according to Ph. Eur., method 2.2.31 and USP <726>; the detection of proteins in the gel is performed by an adapted Coomassie staining or by Silver staining. *Test samples:* Reconstitute FCMtb in purified water at 40 or 20mg/ml concentration. *Reference solutions:* Molecular weight marker, Purified antigens, FCMtb reference standard

Purified Antigens
M. tuberculosis HSP70 protein (Rv 0350)
M. tuberculosis 38 KDa protein (Rv0934)
M. tuberculosis Ag85B protein (Rv1886c)
M. tuberculosis 19 kDa protein (Rv 3763)
M. tuberculosis CFP10 protein (Rv3874)
M. tuberculosis ESAT6 protein (Rv3875)

25

**Table 4:** Reference antigens

For Coomassie staining, Gel-Code Blue Stain reagent solution (Pierce) is used according to the manufacturer's instructions. For Silver Staining, the PROTSIL1 Kit from Invitrogen is used according to the manufacturer's instructions. For

30

Western Blot analysis, proteins are separated by SDS PAGE according to standard methods known in the art and then electrophoretically transferred onto a PVDF membrane for immunodetection using specific monoclonal antibodies. The interaction antigen-antibody is visualized by incubation with an anti-antibody which triggers a chemiluminescent reaction. Antigens from Lionex (Braunschweig, Germany) (M. tuberculosis HSP70 protein (70 kDa), M. tuberculosis 38 kDa protein, M. tuberculosis Ag85B protein (30 kDa), and specific monoclonal antibodies anti-HSP70, anti-38kDa, and anti-Ag85B from Lionex are used.

10 e) *Identification of mycolic acids*

Mycolic acids in FCMtb are examined by one-dimensional TLC, following the Ph. Eur., method 2.2.27. Test samples: Lyophilised FCMtb, 40 mg. Reference solutions: Mycolic acid standard (Sigma). Procedure:

- 15 a) Extraction process: The sample is extracted with chloroform:methanol (1:1) and then it is incubated overnight. The supernatant fraction is eliminated.
- b) Mycolic acid esterification: 2mL of methanol: toluene: sulphuric acid (30:15:1; vol/vol) is added on each tube, and esterification is achieved overnight. Then, 4mL of n-hexane is added. It is dried under nitrogen flow and it is resuspended with 500 µl hexane.
- 20 c) TLC: 10 µl of each sample is applied on a line parallel to the edge of the plate (Silica gel 60 (20x20 cm) (Merck). The chromatographic separation is performed in a saturated tank with a mobile phase (ethyl ether: n-hexane (15:85, vol/vol)) by three times. Then, the plate is allowed to dry in air.
- 25 d) Mycolic acids are revealed by spraying the plates with a solution of phosphomolybdic acid in 96° ethanol and heat at 120°C for 10 min.

Mycolic acids in FCMtb samples are determined by comparison with mycolic acid commercial standard spot. Results are expressed as qualitative data (presence (positive) /absence (negative) of mycolic acid assessed.

30

f) *Identification of trehalose 6,6'-dimycolate (TDM):* Test samples: Lyophilised FCMtb, 40 mg. Reference solutions: TDM standard (Sigma). Procedures

- (i) Extraction process: The sample is extracted with chloroform:methanol (1:1; vol/vol) and then it is incubated overnight. The supernatant fraction is dried under nitrogen flow and it is weighted. Finally, dried samples are resuspended in chloroform at 40 mg/ mL final concentration.
- 35

(ii) TLC: 10 µl of each sample is applied on a line parallel to the edge of the plate (Silica gel 60 (20x20 cm) (Merck). The chromatographic separation is performed in a saturated tank with a mobile phase (chloroform:methanol:water (60:12:1; vol /vol). Then, the plate is allowed to dry in air.

5 (iii) Detection: The TDM is revealed by spraying the plates with a solution of antrone 1% in sulphuric acid and heat at 120°C for 5 minutes.

(iv) Identification: TDM in FCMtb samples is determined by comparison with commercial TDM which is used to generate a standard spot. Results are expressed as qualitative data, i.e. presence (positive)/absence (negative) of TDM assessed.

10

g) *Identification of lipoarabinomannan (LAM):* For Western Blot analysis of LAM, compounds are separated by SDS PAGE according to standard methods and then electrophoretically transferred onto a nitrocellulose membrane for immunodetection using specific antibody CS35. The interaction antigen-antibody is visualized by incubation with an anti-antibody (IgG Goat anti-mouse IR Dye 800 CW) which triggers a fluorescent reaction.

15

#### h) *Sterility*

20 All processes which require sterility, according to the knowledge of the person skilled in the art, are carried out under sterile conditions; this also applies if sterility is not explicitly mentioned for any given step which requires the same. Sterility test is assessed as prescribed in Ph. Eur. 2.6.1 (USP <71>).

#### 25 i) *Mycobacteria inactivation*

The inactivation of mycobacteria is assessed in accordance with Ph. Eur. 2.6.2

#### j) *Bacterial endotoxins*

30 The test for bacterial endotoxins (LAL test, Limulus Amoebocyte Lysate) is performed according to the general indications of the Ph. Eur., method 2.6.14, following Method D (Chromogenic kinetic method) as well as USP <85>.

#### Fragmentation of the bacilli

35 The choice of fragmentation of the bacilli is thought to allow optimal presentation of cell antigens, particularly cell wall antigens. Fragmentation of the FCMtb is determined by both Dynamic Light Scattering (as described below) and Laser diffraction methodologies.

Laser diffraction allows measuring the fragmentation in a range between 0.04  $\mu\text{m}$  and 2000  $\mu\text{m}$ . The assay is carried out in the Servicios Científico-Técnicos de la Universitat de Barcelona, Spain. Instrument: Coulter LS 13320 equipped with a Universal Liquide  
5 Module (ULM). Solvent: purified water / mineral oil. Results: plotted as a histogram, expressing the relative frequency of the number of particles (%) in front of the particle diameter (0.04  $\mu\text{m}$  - 2000  $\mu\text{m}$ ).

#### Determination of z-average particle size and polydispersity index

10

The average particle size as described in this document is determined by dynamic light scattering (DLS), which is based on the physical concept of the Brownian motion of particles, defined in the Stokes-Einstein equation:

15

$$d(H) = \frac{kT}{3\pi\eta D}$$

where:-

$d(H)$  = hydrodynamic diameter

$D$  = translational diffusion coefficient

20

$k$  = Boltzmann's constant

$T$  = absolute temperature

$\eta$  = viscosity

25

Without wishing to be limited to any particular theory, the Stokes-Einstein equation establishes that particles suspended in a liquid medium are in a constant and random  
30 movement, with a speed that depends on their size: the larger the particle is, the slower the Brownian motion will be.

30

In dynamic light scattering measurements, the sample containing the particles to be measured is illuminated with a monochromatic light source, preferably a laser, and  
35 analyzed in a correlation function how the intensity of scattered light fluctuates with time. If, for instance, large particles are being measured, as they move slowly, the intensity of scattered light fluctuates slowly, and the correlation takes long time to decay; on the other hand, if small particles are being measured, as they move quickly, the intensity of scattered light fluctuates quickly, and the correlation of signal decays more rapidly.

35

According to this invention, the particles are preferably measured with the following instrument: Zetasizer nano zs (Malvern Instruments), using purified water / mineral oil as solvents.

5 If nothing to the contrary is indicated, the instrument is used according to the manufacturer's instructions, and adjustment and calibration, if applicable, are also according to the manufacturer's instructions.

10 The size is calculated from the correlation function using various algorithms. In the present case, the 'cumulants analysis', as defined in ISO13321 Part 8 is applied. The correlation function fits results in a single exponential curve that allows for calculation of the following parameters:

- 15 - The mean size, or *z-average* diameter, of the particle distribution. This mean size is the intensity mean.
- The *polydispersity index* (pdi), i.e. corresponding to the width of the particle size distribution.

20 The results are typically plotted as a histogram, expressing the relative frequency of the number of particles (%) with respect to the particle diameter which may be any diameter which is comprised in the range from 1 nm to 3  $\mu\text{m}$ .

#### Potency tests

25 Specific-pathogen-free, 6-7-week-old female C57BL/6 mice are provided by Harlan Iberica (Spain). Test sample: formulation of table 3 and placebo (vaccine formulation without active component).

30 a) *In vivo M. tuberculosis* infected murine model vaccinated with a single dose: The experimental design consists of: Day 0: Subcutaneous infection on lower abdomen of mice with Mtb strain H37Rv Pasteur ( $4 \times 10^4$  CFUs). Day 14: Chemoprophylactic treatment of the animals with a single oral dose of rifapentine (25mg/kg) and Isoniazid (10mg/kg) thus leading to an antibiotic effect of 1 week. Day 21: Vaccination with a single dose of vaccine/Placebo and/or H<sub>2</sub>O subcutaneously in the neck. All the samples are obtained and analyzed for individual mice. Each  
35 experiment includes: a basal group of infected mice plus placebo and the experimental group of infected mice plus vaccination. The groups consist of 6-7



animals, and the experiments are performed in duplicate. Day 28: Animals are anesthetized with isofluorane.

- 5 b) *In vivo M. tuberculosis* infected murine model vaccinated with two doses: The experimental design consists of: Day 0: Subcutaneous infection on lower abdomen of mice with Mtb strain H37Rv Pasteur (4x10<sup>4</sup> CFUs). Day 14 Chemoprophylactic treatment of the animals with a single oral dose of rifapentine (25mg/kg) and Isoniazid (10mg/kg) thus leading to an antibiotic effect of 1 week. Day 21 Vaccination with a first dose of vaccine/Placebo and/or H<sub>2</sub>O subcutaneously in the neck. Day 36: Vaccination with a second dose of vaccine/Placebo and/or H<sub>2</sub>O subcutaneously in the neck. All the samples are obtained and analyzed for individual mice. Each experiment includes: a basal group of infected mice plus placebo and the experimental group of infected mice plus vaccination. The groups consist of 6-7 animals, and the experiments are performed in duplicates. Day 42  
10  
15 Animals are anesthetized with isofluorane.

For both a) and b) above, following sacrifice, the *ex vivo* analysis of interferon- $\gamma$  Spot Forming Units (SFU) parameter by ELISPOT is performed using spleen cell suspensions for cellular immune response.

20

Determination of immunogenic potency in *M. tuberculosis* healthy murine model. Specific-pathogen-free, 6-7-week-old female C57BL/6 mice are provided by Harlan Iberica (Spain). *In vivo M. tuberculosis* healthy murine model vaccinated with two doses. The experimental design consists of: Day 0 Vaccination with a first dose vaccine according to the preferred mode of carrying out this invention, or Placebo and/or H<sub>2</sub>O subcutaneously in the neck. Day 21 Vaccination with a second dose of vaccine/Placebo and/or H<sub>2</sub>O subcutaneously in the neck. All the samples are obtained and analyzed for individual mice. Each experiment includes: a basal group of healthy mice plus placebo and the experimental group of healthy mice plus vaccination. Day 28 Animals are anesthetized with isofluorane. After  
25  
30 sacrifice, the analysis of IgGs antibodies by ELISA is performed using mouse serum for humoral immune response.

#### Diagnosis of tuberculosis

Methods for diagnosis of tuberculosis are well known to the skilled person. The  
35 Quantiferon test and the TST are known to deliver reliable results and may be used alone or in combination for categorizing subjects for their suitability to be subjected to therapy with the product of the present invention. QuantIFERON, also known as QFT, is a

commercially available test for tuberculosis infection or latent tuberculosis, manufactured by Cellestis Limited, Chadstone, Melbourne, Victoria, Australia. QFT is an interferon- $\gamma$  release assay (IGRA) used in tuberculosis diagnosis. It is used according to the manufacturer's instructions. The Mantoux test (also known as the Mantoux screening test, Tuberculin Sensitivity Test, (TST test), Pirquet test, or PPD test for Purified Protein Derivative) is a diagnostic tool for tuberculosis. An overview of both tests can be found in Franken *et al.*, Clin Vaccine Immunol. 2007, April; 14(4): 477–480.

#### Examples:

The Examples below are given to provide the person skilled in the art with a workable mode and explanation of some specific embodiments of the invention. These Examples have illustrative purpose and do by no means intend to limit the scope of the invention in any way.

#### Example 1: Isolation of the strain *Mycobacterium tuberculosis* NCTC 13536

The starting material for the production of FCMtb is an inoculum of the strain NCTC 13536, synonymously called 511 or *Mycobacterium tuberculosis* NCTC 13536, a strain of *Mycobacterium tuberculosis* isolated from an immunocompetent patient diagnosed with pulmonary tuberculosis in Barcelona, Spain. It was deposited in 2010 at the NCTC in London, which is an official depositary organisation according to the Budapest Treaty. The strain has additionally been deposited by the strain collection of the Service of Microbiology of the Hospital de Sant Pau, Barcelona, Spain.

Two passages of the original strain have been performed in the years 1995, and 1996 respectively. MSL PB#1 corresponds to the second passage of the original strain of *M. tuberculosis* NCTC 13536, which was performed in October 1996 resulting in 100 vials (3 ml sterile glass vials) stored at  $-70 \pm 5^\circ\text{C}$ . The strain has a low genetic polymorphism, as identified by standard methods in the art.

#### Example 2: Upstream process for production of MTB-C cells

A flow-chart of this process is given in Figure 1. The starting material for the production of FCMtb is an inoculum of the strain *Mycobacterium tuberculosis* NCTC 13536 (Example 1). In order to ensure the continued supply of this starting material, a seed lot system is preferably used. Hence, a working seed lot (WSL) derived from a master seed lot (MSL) is

used for production of FCMtb. *Mycobacterium tuberculosis* NCTC 13536 (Example 1) is cultured for 3 - 5 weeks in Löwenstein-Jensen medium. The bacterial growth is then sub-cultured in Proskauer Beck media at  $37 \pm 2^\circ\text{C}$  with stirring at  $100 \pm 5$  rpm. Once the maximum bacterial concentration (by visual inspection) is achieved, a subculture in Proskauer Beck media is started and incubated. When a similar bacterial concentration is achieved, small aliquots are taken. The viable bacterial count is determined by the number of colony forming units (CFUs) obtained in Middlebrook agar medium after incubation at  $37 \pm 2^\circ\text{C}$  for 3 - 4 weeks. The bacterial count must be  $2 - 5 \times 10^7$  CFUs/ml.

10 (1) Culture of *Mycobacterium tuberculosis*

The production of FCMtb begins with the seeding of 0.2 ml of a WSL in a 7H11 agar plate and incubation at  $37 \pm 1^\circ\text{C}$  for  $15 \pm 2$  days. Then, colonies are transferred into a tube containing a few glass beads. After mixing, approximately 5 ml of water for injection (WFI) is added to obtain a bacterial suspension. At this point, a viable plate count and a sterility test are performed. About 100 Middlebrook 7H11 agar plates are seeded with *M. tuberculosis* using swabs soaked with the bacterial suspension to obtain confluent cultures. The plates are incubated at  $37 \pm 1^\circ\text{C}$  for  $21 \pm 2$  days.

Sterility test as in-process control is performed as follows:

20 The sterility testing is aimed to ensure the absence of fungi and bacteria other than *Mycobacteria*. The tests are carried out by direct inoculation, following the conditions described in Ph. Eur. 2.6.1 for the sterility test. Samples tested must be sterile. Medium 7H11 is used instead of 7H10 (as is mentioned in Ph. Eur. 2.6.2). 7H11 is based on medium 7H10 adding one gram of pancreatic digest of casein in order to enhance the growth of strains of *Mycobacterium tuberculosis*.

(2) Harvest of *Mycobacterium tuberculosis* and freezing of crude extract

After the incubation period, the purity of the bacterial culture is controlled by a visual inspection of the agar plates and the performance of a sterility test. Then, bacterial growth is collected from agar plates and transferred into a sterile tube. The crude extract obtained is weighed (20-22 g). The mixture is kept at  $-80^\circ\text{C} \pm 5^\circ\text{C}$ .

Example 3: Downstream process for production of liposomes obtained from the crude extract

35

A flow-chart of this process is given in Figure 2.

(3) Cell fragmentation and de-lipidation

The frozen crude extract (Example 2) is thawed at  $37 \pm 1^\circ\text{C}$  and sterile PBS buffer with 4% (w/w) Triton-X114 (pH 7.0 -7.5) is then added at  $4^\circ\text{C}$ . After mixing, it is subsequently transferred into a sterile polycarbonate container containing sterile silica/zirconia beads. Then, cell fragmentation is carried out in a Beadbeater by applying the following  
5 fragmentation method: 3 cycles, each one consisting of 5 periods ON/OFF plus 10 minutes of break. Once the process is finished, the cellular fragmented fraction is separated from the beads by subsequent washings (repeated shaking and sedimentation) in sterile PBS buffer with 4% triton-X114, (pH 7 - 7.5). An aliquot of the washed suspension of the cellular fragmented fraction is then collected for pH control and a final  
10 centrifugation at 845 g at  $4^\circ\text{C}$  for 30 minutes proceeds.

To remove the cytosolic fraction and to obtain a suspension enriched in cellular fragments, a high speed centrifugation is performed twice at 20000 g approx. for 60 minutes, at  $4^\circ\text{C}$ . After the first centrifugation, the yellowish supernatant (rich in soluble proteins and lipids) is discarded and the pellet is resuspended in PBS and further  
15 centrifuged under the same above described conditions. After that, the appearance of the discarded supernatant must be clear and colourless. Finally, the obtained pellet is resuspended in a final volume of 50 - 60 ml PBS (FCMtb suspension)

#### (4) Pasteurization

The FCMtb suspension is then pasteurized at  $65 \pm 2^\circ\text{C}$  for 60 min. Once pasteurization is  
20 finished pH of the pasteurized FCMtb is determined by litmus paper. It is considered acceptable in the range pH 6.5 - 7.5. Sterile and depyrogenated vials are filled with 0.5 ml of the product suspension and IPCs on Sterility and *Mycobacteria* inactivation are performed. Finally, filled vials are frozen at  $-80 \pm 5^\circ\text{C}$ . Once the material is subjected to pasteurisation, it will be physically segregated from untreated material, i.e. the spaces  
25 used before pasteurisations are clearly separated from those used during the subsequent filling process.

#### (5) Freeze-drying

All vials containing the product frozen are then lyophilised at about  $-45^\circ\text{C}$  to  $30^\circ\text{C}$   
30 temperature and at 0.310 mbar pressure for approximately 18 hours (0.5 ml volume per vial). Using aseptic techniques and under  $\text{N}_2$  atmosphere, the vials are stoppered and labelled. The packaged drug substance is then stored at  $-20^\circ \pm 5^\circ\text{C}$  for up to 12 months.

#### Example 4: Protein characterization

35

Figure 3 gives an overview of the characterisation strategy in terms of protein profile.

Based on literature (Andersen P., 1997, Scand J. Immunol.; 45(2):115-31; Geisel et al., 2005, J. Immunol.; 174(8):5007-15; Stewart et al. 2005, Infect. Immun., 73(10):6831-7., Wang et al., 2007, J. Mol. Biol., 366(2):375-81), 6 protein bands were selected as being representative for protein profile assessment: HSP70 protein (Rv0350), 38 kDa protein (Rv 0934), (Rv 1866c), 19 kDa protein (Rv 3763), CFP10 protein (Rv3874), and ESAT-6 protein (Rv3875).

A. Determination of total protein content: Total protein levels in FCMtb are quantified by bicinchoninic acid (BCA) methodology. Total protein represents about 10% (w/w) of FCMtb content. Reference standards FCMtb-0429-16 and FCMtb-52.1 contain 167 µg protein/mg FCMtb and 115 µg protein/ mg FCMtb, respectively.

B. Identification of protein profile by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE): The protein profile of the drug substance FCMtb was determined by comparison with reference antigens from *Mycobacterium tuberculosis* corresponding to ESAT6 (6 kDa) (7); CFP10 (10 kDa) (6); Ag85B (30 kDa) (1); 38kDa (2); HSP70 (70 kDa) (4) as well as Molecular Weight marker MW (5), are shown (see Figure 4). Determination of protein profile of drug substance FCMtb and identification of bands (approximately 70 kDa, 38 kDa, 30 kDa, 10 kDa and 6 kDa) is carried out by Coomassie staining. Identification of the 19 kDa band (lipopolypeptide) is carried out by silver staining.

C. Identification of the protein profile by Western-blot with specific monoclonal antibodies: The protein profile of the drug substance FCMtb is determined by the patterns obtained using Western-blot analyses with monoclonal antibodies (mAb): Anti-HSP70 (70 kDa, Fig. 5c), anti-38kDa (Fig. 5d), anti-Ag85B (30 kDa, Fig. 5e).

FCMtb-52.1 is the reference batch for FCMtb according to the preferred mode of carrying out this invention.

#### Example 6: Lipid characterisation

The characterisation of the lipid profile of FCMtb consists of a fractionating process based on chloroform:methanol (1:1) extraction. The fractionating process carried out in these studies has been based on the procedure described by Delmas et al., 1997, *Glycobiology* 7(6), 811-7. Thin layer chromatography (TLC) has been the method used to analyse the content of lipids and glycolipids present in FCMtb. Specifically, polyaciltrehalose (PT), trehalose dimycolate (TDM), diacyltrehalose (DAT), phosphatidilinositolmannosids (PIMs) and other phospholipids, as well as phthiocerol dimycocerosates (PDIM) and Mycolic

acids have been identified by thin layer chromatography (TLC) both in the reference strains H37rv and NCTC 13536, as well as in different FCMtb batches. See figure 7a. The content of trehalose 6,6'-dimycolate (TDM) is analysed by TLC in the supernatant. Mycolic acids determination is conducted in the sediment, following a TLC method. Although no quantitative data are known for the lipid profile of MTB-C, the qualitative lipid profile established in the studies is in line with current scientific knowledge and allows for a standard characterisation of the immunogenic lipids so far known. FCMtb have been compared with whole cell lipid fraction of strains NCTC 13536 and H37Rv of *M. tuberculosis* and TDM commercial standard (see Figure 7a and 7b). Overall, the lipid content has been shown to be consistent in different batches of FCMtb-comprising liposomes according to this invention. Figure 7d shows the identification of LAM.

#### Example 6: Characterization of fragmented cell material

Preliminary results using both methodologies show that the fragments size of FCMtb is mainly below 1  $\mu\text{m}$  (99% < 1  $\mu\text{m}$ ) which is corroborated by FCMtb electronic microscopy: the fragment size ranges mainly from 100 to 300 nm.

Levels of residual DNA after extraction with a phenol/chloroform mixture have been investigated by absorbance at 260 nm (detection limit: 0.2  $\mu\text{g}$  DNA/mg FCMtb). Typical results obtained so far are below 15  $\mu\text{g}$  DNA/mg FCMtb.

The consistency of the production process of the drug substance is shown by a lipid and protein profile that is reproducible for different FCMtb batches.

#### Example 7: Immunisation of mice and visualization of biological activity

Interaction of protein bands of FCMtb with mouse immunoserum: Using Western-blot methodology it has been possible to visualize FCMtb protein bands that interact with IgG antibodies present in serum obtained from infected mice inoculated twice with the liposome-formulation based vaccine according to this invention. This is considered to be an indicator for the biological activity (Figure 6).

#### Example 8: *In vivo* activity of a liposome formulation comprising FCMtb

The biological activity of the vaccine is studied in an *in vivo* model by evaluating the immunogenic potency of FCMtb without liposomes (reconstituted with water for injection, WFI) and with FCMtb in the liposome formulation according to the best mode of carrying out the present invention (5 % sucrose, see above) (Figure 8). These results show the advantages of the liposome formulation with sucrose.

The aggregation or fusion states of liposomes are parameters which have been demonstrated to have a significant impact on the biological activity of the vaccine. Therefore, the researchers of the present invention perform an exhaustive control of particle size and polydispersity index during the manufacturing and at batch release of the vaccines.

#### Example 9: Effect of sucrose

In an initial test, one of the following excipients (a) 1.5% glycine and (b) 5% sucrose, respectively, was optionally incorporated into a liposome formulation comprising fragments of the MTB-C strain NCTC 13536. Subsequently, a comparative evaluation is undertaken on physicochemical properties and biological activity associated to both formulations.

Results obtained by measurement after reconstitution of the lyophilized liposome composition and after testing according to the current batch release specification parameters are presented in Table 5.

Parameter		Acceptance criteria	FCMtb formulated in a liposome suspension			
			Without excipient	Sucrose 5%	Glycine 1.5%	
			FCMtb formulated in a liposomal suspension			
<i>Appearance</i>		White to off-white powder	ND	Complies	Complies	
<i>Cake morphology</i>		Flat to almost flat and homogeneous	ND	Complies	Complies	
<i>Water content (%)</i>		≤ 3 %	ND	1.4	3.0	
<i>Time to reconstitution (s)</i>		Well reconstituted ≤10s	ND	5	12	
<i>pH</i>		7-8	8.1	7.4	7.0	
<i>Particle size</i>	<i>z-average (nm)</i> <i>Pdi<sup>(a)</sup></i>	75 ± 20 (≤ 0.250)	370 <sup>(1)</sup> (0.492)	66 (0.215)	504 <sup>(1)</sup> (0.569)	
<i>Immunogenic potency in M. Tuberculosis infected murine model</i>	<i>Antigen-specific IFN-γ Spot forming units</i>	PPD	3-12 Ratio SFU/10 <sup>6</sup> cells with respect to basal value (Basal value in SFU/10 <sup>6</sup> cells)	3.6 (183)	5.1 (183)	2.8 (183)
		Ag85B (30 kDa)	5-20 Ratio SFU/10 <sup>6</sup> cells with respect to basal value (Basal value in SFU/10 <sup>6</sup> cells)	5.5 (73)	9.6 (73)	5.4 (73)

<sup>(a)</sup> Polydispersity index<sup>(1)</sup> Presence of liposomal aggregates  
ND = not determined

**Table 5:** Results of specifications for 3 different formulations, measured after reconstitution of the lyophilized liposome composition.



The investigators of this study surprisingly found that 5% sucrose formulation provides the advantage of better physicochemical results, such as water content or time to reconstitution, respectively. But the most crucial fact is the important reduction in liposomal aggregation (particle size, z-average) shown with the sucrose-comprising formulation in comparison with the other two formulations. Analysis by Dynamic Light Scattering has shown a z-average of  $75 \pm 20$  nm (polydispersity index  $\leq 0.350$ ) of the sucrose-containing liposomes. Electron microscopy of freeze-fracturing preparations of the sucrose-containing liposome formulation shows a mixture of multilamellar and unilamellar liposomes with sizes between 40 and 100 nm (Figure 9).

Due to this improved parameter together with the observed lesser water content levels ( $\leq 2\%$ ) for the 5% sucrose formulation, improved stability results are expected for this formulation. This is indeed the case. Data of the investigators of the present study of experimental batches formulated with 1.5% glycine stored at room temperature for 3 months have indicated a drastic loss of biological activity for PPD (immunogenic potency). By contrast, the biological activity for PPD remains basically unchanged when the 5% sucrose-comprising formulation is studied after 3 months storage at room temperature. Hence, sucrose also provides the advantage of better maintenance of the biological activity.

#### Example 10: Biological properties of the sucrose-comprising formulation

The formulation according to Table 3 was used for biological studies. The cellular immune response triggered by inoculation of vaccine according to the preferred mode of carrying out this invention (single inoculation) in a *Mycobacterium tuberculosis* infected murine model can be measured by ELISPOT, results are given in Table 6.

Parameter		Batch (50 µg/dose, 166.7 µg/mL)			
		a09	c09	d09	e09
<b>Antigen-specific IFN-γ Spot forming units (SFU)</b>	PPD Ratio SFU/10 <sup>6</sup> cells with respect to basal value (Basal value: SFU/10 <sup>6</sup> cells)	5.1 (Basal: 183 SFU/10 <sup>6</sup> cells)	6.3 (Basal: 98 SFU/10 <sup>6</sup> cells)	7.2 (Basal: 164 SFU/10 <sup>6</sup> cells)	6.5 (Basal: 164 SFU/10 <sup>6</sup> cells)
	Ag85B Ratio SFU/10 <sup>6</sup> cells with respect to basal value (Basal value: SFU/10 <sup>6</sup> cells)	9.6 (Basal: 73 SFU/10 <sup>6</sup> cells)	9.9 (Basal: 44 SFU/10 <sup>6</sup> cells)	11.9 (Basal: 90 SFU/10 <sup>6</sup> cells)	12.3 (Basal: 88 SFU/10 <sup>6</sup> cells)

ND: Not determined.

**Table 6:** Cellular response after inoculation in mice.

5 Inoculation of the liposome formulation based vaccine leads to a significant increase of cellular immune response in vivo compared to basal values of infected animals when ELISPOT is used for determination of response levels. The ratio with respect to basal response is 4-8 fold for PPD and 8 to 14 fold for Ag85B. The liposome formulation based vaccine is also able to induce a polyantigenic humoral response, which has a protective effect specially when there is a high dissemination of the infection (Guirado et al., 2006, 10 *Microbes Infect.* 8, 1252-1259).

A comparison was specifically made between the data of immunogenic potency obtained with the formulation with no sucrose versus the formulation which contains sucrose as major excipient. The results obtained clearly indicate that the cellular immune response 15 elicited by a 50 µg FCMtb dose of the formulation with sucrose is approximately 1.5-fold higher than that obtained with an identical dose of the formulation without sucrose in a single vaccination model. These higher levels of cellular immune response are obtained in both potency tests: the one conducted for batch release specifications (a single vaccination model) and the additional test included for comparability exercise (model 20 vaccinated twice). Moreover, in both potency tests, the cellular immune response elicited by 50 µg FCMtb dose of the formulation with sucrose shows similar levels to those obtained with the 200 µg FCMtb of the sucrose-free formulation. Results, measured after reconstitution of the lyophilized liposome composition are given in Figure 10a and 10b. The sucrose-comprising formulation shows a significant reduction of liposomal 25 aggregation. This is believed to be the reason for the increase in immunogenicity. The cellular immune response achieved with a 50 µg dose of the new formulation is almost comparable to that seen with a 200 µg dose obtained with the sucrose-free formulation. It is known in the field that the cellular response is considered to be the relevant response (North RJ, Jung YJ (2004). *Annu. Rev. Immunol.* 22: 599-623).

30

#### Example 11: Manufacturing process of the lyophilized liposome formulation

One embodiment of the manufacturing process of a pharmaceutical composition comprising the liposome formulation according to the present invention is shown in Figure 35 11a and 11b. Briefly, it comprises the following steps 1 to 5.

(1) Preparation of the LCS bulk components

LCS bulk soy lecithin is dissolved in ethanol (1:1; w/w) and sodium cholate is dissolved in water (1:5; w/w). The solutions are sterilized by filtration. After mixing of sodium lecithin solution and sodium cholate solution, lyophilised FCMtb (Example 1) is added upon stirring. The ratios of the components are 0.03:0.2:0.7 (FCMtb:sodium cholate:soy lecithin; w/w/w).

#### (2) LCS bulk preparation

The aqueous phase of is transferred to a sterilised stainless steel mixer. The lipid phase of (1), containing soy lecithin, sodium cholate, and FCMtb, is added in a ratio 0.7:0.3(aqueous phase:lipid phase, w/w). The phases are mixed at 2200 rads/s for 3 min for homogenisation and liposome formation. After homogenisation, the bulk LCS is transferred to another vessel and allowed to stand for at least 5 minutes. An IPC on particle size is performed on the LCS bulk.

#### (3) Dilution of LCS bulk, final formulation of liposome suspension

A 10% (w/w) solution of sucrose is prepared and sterilized. The sucrose solution is mixed with water and LCS bulk in the adequate proportions to get the final liposome suspension (LS) bulk constituted of 21 mg LCS/ml in 5% sucrose solution. pH, sterility, and particle size are tested as in-process controls.

#### (4) Filling

Vials are filled with 0.4 ml of LS (under continuous agitation) and partially closed for freezing and lyophilisation.

#### (5) Lyophilisation, packaging, and labelling

Vials are frozen at  $-80^{\circ}\text{C} \pm 5^{\circ}\text{C}$  until lyophilisation proceeds. The lyophilisation process is performed in the range of  $-45^{\circ}\text{C}$  to  $25^{\circ}\text{C}$  temperature and 0.150 mbars. The process lasts for 24 hours. At the end of lyophilisation vials are fully stoppered in  $\text{N}_2$  atmosphere, encapsulated, labelled and stored at  $5^{\circ}\text{C} \pm 3^{\circ}\text{C}$ .

#### Example 12: Adjunctive therapy against LTBI will require only a single shot of 25 $\mu\text{g}$ of FCMtb

A Phase II double blind randomized clinical trial was set to evaluate 3 doses of FCMtb (5, 25, 50  $\mu\text{g}$ , each prepared as described in the preferred mode of carrying out this invention) and placebo in 96 HIV positive (HIV+) and HIV negative (HIV-) subjects with latent tuberculosis infection (LTBI) (TST+ and Quantiferon+) that were randomly allocated

in groups of n=12 per arm after receiving 1 month treatment of isoniazid. Subjects were inoculated twice with FCMtb (5, 25, 50 µg, each prepared as described in the preferred mode of carrying out this invention), immediately following isoniazid chemotherapy and 4 weeks apart.

5

Immunological profile: FCMtb (5, 25, 50 µg, each prepared as described in the preferred mode of carrying out this invention) elicited a bell-shaped, poly-antigenic response against secreted (ESAT-6, Ag85B) and structural (16 kDa, 38 kDa) antigens that were stimulated in all the doses (Figures 12 and 13). FCMtb (5, 25, 50 µg, each prepared as described in the preferred mode of carrying out this invention) elicited also a long term memory response (the WHO test) at the higher doses, compatible with a prophylactic effect. Surprisingly, although globally immune responses were more intense in HIV- than in HIV+, the single inoculation of 25 µg of FCMtb (5, 25, 50 µg, each prepared as described in the preferred mode of carrying out this invention) elicited the best immune response in both populations (Figures 12 and 13).

10

15

Conclusion: A single inoculation of 25 µg is the best choice for adjunctive therapy against LTBI in HIV negative and HIV positive subjects.

Brief description of the drawings

Figure 1: Flow-chart showing upstream process of the drug substance FCMtb, including the materials and reagents involved in the process and suitable in-process controls.

5

Figure 2: Flow-chart showing downstream process of the drug substance FCMtb, including the materials and reagents involved in the process and suitable in-process controls.

10 Figure 3: Flow-chart of protein characterization.

Figure 4: Identification of antigens by SDS-PAGE and Coomassie Blue Stain methodology. Reference antigens ESAT6 (6 kDa) (7); CFP10 (10 kDa) (6); Ag85B (30 kDa) (1); 38kDa (2); HSP70 (70 kDa) (4) as well as Molecular Weight marker MW (5), are shown.

15

Figure 5: Protein characterisation. Figure 5a: Protein profile: Protein profile of reference standard FCMtb-52.1 (1 to 6) at final concentrations of 15.6 µg FCMtb/mL (1, 2), 6.25 µg FCMtb/mL (3, 4) and 1.56 µg FCMtb/mL (5, 6), SDS page followed by Coomassie stain. MW in kDa. 5b: Identification of the 19 kDa band, SDS page followed by silver staining. 5c: Protein profile: Identification of bands (10 kDa and 6 kDa) in the indicated FCMtb batches by SDS-PAGE and Silver Stain methodology carried out in parallel with ESAT-6 standard from Lionex. Different FCMtb batches (1, 2, 3, 9, 10, 11, (batch FCMtb-52.1 in lane 9)), ESAT-6 standard from Lionex at different concentrations (4 to 8); 5d: Western Blot Identification of antigen *M. tuberculosis* HSP70 (Rv 0350) in FCMtb batches by Western-blot using specific antibodies parallel to *M.tuberculosis* HSP70 standard. Different FCMtb batches (1, 2, 3,4, 7, 8, 9), HSP70 standard (5,6); 5e: Identification of antigen *M. tuberculosis* 38 kDa (Rv 0934) in FCMtb batches by Western-blot methodology using a specific antibody and carried out in parallel with *M.tuberculosis* 38 kDa standard from Lionex. Fluorescence detection using the Odyssey System. Different FCMtb batches (1, 2, 3, 6, 7), 38 kDa standard (4, 5). 5f: Identification of antigen Ag85B (Rv 1886c) in FCMtb batches by Western-blot methodology using a specific antibody and carried in parallel with *M.tuberculosis* Ag85B standard from Lionex. Fluorescence detection using the Odyssey System. FCMtb batches (1, 2, 3, 5, 6, 7), Ag85B standard (4).

20

25

30

35

Figure 6: Interaction of indicated protein bands of different FCMtb batches (50 µg/lane) with 1/8000 diluted serum obtained from infected mice after being inoculated twice with

the liposome formulation based pharmaceutical vaccine composition according to this invention, using Western-blot methodology.

5 Figure 7: Lipid analysis. 7a: Identification of polyacyltrehalose (PT), trehalose 6,6'-dimycolate (TDM) and diacyltrehalose (DAT) in reference strains (H37Rv (2) and NCTC 13536 (1) and different FCMtb batches (3-9), and TDM standard (10) by TLC methodology. 7b: Identification of trehalose 6,6'-dimycolate (TDM) in FCMtb batches by TLC methodology. Panels (A) and (B) represent two independent assays. (A) TDM standard (11) and (12), other lanes different FCMtb batches. B: (1) TDM standard (1),  
10 other lanes different FCMtb batches. 7c: Pattern of mycolic acids I, III and IV in FCMtb batches by TLC methodology. Panels (A), (B) and (C) represent three independent assays. (A) FCMtb batches (1-6 (FCMtb-51.2 standard 6)). (B) for illustration/reference, (C) batch FCMtb-47b (1) compared with mycolic acid standard (2). 7d: Identification of LAM (reference in left lane, samples derived from liposomes according to the invention in  
15 remaining lanes).

Figure 8: Comparison of cellular immunopotency of FCMtb resuspended with water for injection (WFI) versus FCMtb formulated with liposomes (labelled RUTI vaccine, batch 10a), at the same dose (50 µg/dose).

20

Figure 9: Freeze-fracturing preparation of liposomal concentrate (LCS) bulk (electronic microscopy).

Figure 10: a: Cellular immune response per batch tested with the two formulations of vaccine in a potency test (one vaccination). b: as in a, but two vaccinations. "Formulation II": comprising 5 % (w/w) sucrose, according to Table 1 of this document. "Formulation I": as formulation II, except that no sucrose is present. µg refers to µg FCMtb/dose. 85B: Ag85B.

30 Figure 11: Flow-chart of the process according to the preferred mode of carrying out this invention.

Figure 12: Immunological profile of 1 inoculation of RUTI 25 µg as described in Example 12.

35

Figure 13: Immunogenicity (HIV- and HIV+) as described in Example 12.

Claims

1. A liposome formulation comprising:
- 5 (a) fragments from a *Mycobacterium tuberculosis*-complex (MTB-C) strain,  
(b) a liposome forming agent,  
1 to 20 % (w/v) sucrose, preferably 2 to 12 % (w/v) sucrose, more preferably 3 to 8  
% (w/v) sucrose, and most preferably 4 to 6 % (w/v) sucrose, wherein the z-  
average size of the particles is 120 nm or less.
- 10 2. The liposome formulation according to claim 1, wherein z-average size of the  
particles is in the range from 40 to 110 nm, more preferably from 55 to 95 nm.
3. The liposome formulation according to any of claims 1 or 2, wherein the liposome  
15 formulation is an emulsion, and wherein the z-average size of the particles is  
preferably below 40 nm.
4. The liposome formulation according to any of the preceding claims, wherein the  
polydispersity index of the particles is 0.4 or less, preferably 0.3
- 20 5. The liposome formulation according to any of the preceding claims, wherein the  
*Mycobacterium tuberculosis*-complex (MTB-C) strain is a virulent *Mycobacterium  
tuberculosis*-complex (MTB-C) strain, and preferably the MTB-C strain NCTC  
13536, deposited in 2010 at the NCTC in London.
- 25 6. The liposome formulation according to any of the preceding claims, additionally  
comprising  
(d) a tensioactive agent  
and/or  
30 (e) one or more non-ionic surfactants.
7. The liposome formulation according to any one of the preceding claims, wherein  
the fragments of MTB-C cells are or comprise cell wall fragments.
- 35 8. The liposome formulation according to claim 6, wherein the ratio between (a) and  
(d) is between 0.05:1 and 1:5 (w/w).

9. The liposome formulation according to any of the preceding claims, wherein the liposome forming agent is a hydrogenated, partially hydrogenated or non-hydrogenated phospholipid, preferably lecithin, and most preferably soy lecithin.
- 5
10. The liposome formulation according to any of claims 10 to 12, wherein the tensioactive agent is selected from cholate, deoxycholate, cholesterol and cholesterol hemisuccinate.
- 10
11. The liposome formulation according to any one of the preceding claims, wherein the fragments of MTB-C cells are or comprise cell wall fragments.
12. The liposome formulation according to any one of the preceding claims, comprising fragments of the MTB-C strain NCTC 13536, deposited in 2010 at the NCTC in London.
- 15
13. The liposome formulation according to any of the preceding claims, comprising at least two, preferably three, more preferably four, and most preferably all of the following:
- 20
- (i) a first polypeptide having a molecular weight of about 70 kDa as measured following electrophoresis on a sodium dodecylsulfate (SDS) polyacrylamide gel, wherein the first polypeptide has a mass fingerprint similar to a mass fingerprint of *M. tuberculosis* HSP70 protein (Rv0350),
- (ii) a second polypeptide having a molecular weight of about 38 kDa as measured following electrophoresis on a sodium dodecylsulfate (SDS) polyacrylamide gel, wherein the second polypeptide has a mass fingerprint similar to a mass fingerprint of *M. tuberculosis* 38 kDa protein (Rv 0934),
- 25
- (iii) a third polypeptide having a molecular weight of about 30 kDa as measured following electrophoresis on a sodium dodecylsulfate (SDS) polyacrylamide gel, wherein the third polypeptide has a mass fingerprint similar to a mass fingerprint of *M. tuberculosis* Ag85B protein (Rv 1866c), and
- 30
- (iv) a fourth polypeptide having a molecular weight of about 10 kDa as measured following electrophoresis on a sodium dodecylsulfate (SDS) polyacrylamide gel, wherein the fourth polypeptide has a mass fingerprint similar to a mass fingerprint of *M. tuberculosis* CFP10 protein (Rv3874), and
- 35



(i) a fifth polypeptide having a molecular weight of about 6 kDa as measured following electrophoresis on a sodium dodecylsulfate (SDS) polyacrylamide gel, wherein the fifth polypeptide has a mass fingerprint similar to a mass fingerprint of *M. tuberculosis* ESAT-6 protein (Rv3875).

5

14. The liposome formulation according to any of the preceding claims, wherein at least one of the following antigens of *Mycobacterium tuberculosis*, or fragment thereof, is present: HSP70, 38 kDa protein and Ag85B.

10

15. The liposome formulation according to any of the preceding claims, comprising one or more mycolic acids and/or a sugar-conjugated mycolate, preferably trehalose dimycolate and/or a glycolipid, preferably liporabinomannan.

15

16. The liposome formulation according to any of the preceding claims, additionally comprising one or more non-ionic surfactants.

17. The liposome formulation according to any of the preceding claims, additionally containing one or more salts or a solution thereof, whereby the salt is preferably sodium chloride.

20

18. The liposome formulation according to any of the preceding claims, wherein the liposome formulation is freeze-dried.

25

19. A suspension, wherein the liposome formulation of any of the preceding claims is reconstituted in a solvent, wherein the solvent is preferably aqueous, and more preferably is or comprises physiological serum.

30

20. A pharmaceutical composition comprising the formulation according to any of claims 1 to 18 or the suspension according to claim 19, and a pharmaceutically acceptable carrier or diluent, and/or a pharmaceutically acceptable adjuvant.

35

21. The liposome formulation according to any one or more of claims 1 to 18, the suspension according to claim 19, or the pharmaceutical composition according to claim 20 for use in a method of treatment of the human or animal body by therapy.

22. The liposome formulation, suspension or pharmaceutical composition according to claim 21 for use in a method of treating or preventing tuberculosis.
23. The liposome formulation, suspension or pharmaceutical composition according to claim 22, selected from the following:
- (a) for use in a method of prevention of active tuberculosis in individuals with a latent tuberculosis infection;
  - (b) for use in a method of primary prophylaxis of tuberculosis in order to prevent infection of individuals who had been exposed to the disease, but are not yet infected, or
  - (c) for use in a method of treating or preventing latent tuberculosis.
24. The liposome formulation, suspension or pharmaceutical composition according to any of claims 21 to 23 for administration to the human body in a dose comprising 1 to 1000, preferably 3 to 250, more preferably 4 to 80, and most preferably about 5, about 25 or about 50 µg/dose FCMtb.
25. The liposome formulation, suspension or pharmaceutical composition according to any of claims 21 to 23 for administration to the human body in a single oculation dose of 25 µg FCMtb.
26. The liposome formulation, suspension or pharmaceutical composition according to any of claims 21 to 25 for use in combination therapy, which preferably comprises an antibiotic, more preferably one ore more of isoniazide and an ansamycine, whereby the ansamycine is most preferably rifampicin.
27. The liposome formulation, suspension or pharmaceutical composition of claim 125 for use in adjunctive therapy.
28. The liposome formulation, suspension or pharmaceutical composition according to claim 27 for administration in adjunctive therapy to an HIV positive human subject.
29. The liposome formulation, suspension or pharmaceutical composition according to claim 25 for administration to an HIV negative human subject.

## AMENDED CLAIMS

received by the International Bureau on 19 April 2012 (19.04.2012)

1. A liposome formulation comprising:
  - (a) fragments from a *Mycobacterium tuberculosis*-complex (MTB-C) strain,
  - (b) a liposome forming agent,
  - (c) 1 to 20 % (w/v) sucrose, preferably 2 to 12 % (w/v) sucrose, more preferably 3 to 8 % (w/v) sucrose, and most preferably 4 to 6 % (w/v) sucrose,wherein the z- average size of the particles is 120 nm or less.
2. The liposome formulation according to claim 1, wherein z-average size of the particles is in the range from 40 to 110 nm, more preferably from 55 to 95 nm.
3. The liposome formulation according to any of claims 1 or 2, wherein the liposome formulation is an emulsion, and wherein the z-average size of the particles is preferably below 40 nm.
4. The liposome formulation according to any of the preceding claims, wherein the polydispersity index of the particles is 0.4 or less, preferably 0.3
5. The liposome formulation according to any of the preceding claims, wherein the *Mycobacterium tuberculosis*-complex (MTB-C) strain is a virulent *Mycobacterium tuberculosis*-complex (MTB-C) strain, and preferably the MTB-C strain NCTC 13536, deposited in 2010 at the NCTC in London.
6. The liposome formulation according to any of the preceding claims, additionally comprising
  - (d) a tensioactive agent
  - and/or
  - (e) one or more non-ionic surfactants.
7. The liposome formulation according to any one of the preceding claims, wherein the fragments of MTB-C cells are or comprise cell wall fragments.
8. The liposome formulation according to claim 6, wherein the ratio between (a) and (d) is between 0.05:1 and 1:5 (w/w).

9. The liposome formulation according to any of the preceding claims, wherein the liposome forming agent is a hydrogenated, partially hydrogenated or non-hydrogenated phospholipid, preferably lecithin, and most preferably soy lecithin.
10. The liposome formulation according to any of claims 6 to 8, wherein the tensioactive agent is selected from cholate, deoxycholate, cholesterol and cholesterol hemisuccinate.
11. The liposome formulation according to any one of the preceding claims, comprising fragments of the MTB-C strain NCTC 13536, deposited in 2010 at the NCTC in London.
12. The liposome formulation according to any of the preceding claims, comprising at least two, preferably three, more preferably four, and most preferably all of the following:
  - (i) a first polypeptide having a molecular weight of about 70 kDa as measured following electrophoresis on a sodium dodecylsulfate (SDS) polyacrylamide gel, wherein the first polypeptide has a mass fingerprint similar to a mass fingerprint of *M. tuberculosis* HSP70 protein (Rv0350),
  - (ii) a second polypeptide having a molecular weight of about 38 kDa as measured following electrophoresis on a sodium dodecylsulfate (SDS) polyacrylamide gel, wherein the second polypeptide has a mass fingerprint similar to a mass fingerprint of *M. tuberculosis* 38 kDa protein (Rv 0934),
  - (iii) a third polypeptide having a molecular weight of about 30 kDa as measured following electrophoresis on a sodium dodecylsulfate (SDS) polyacrylamide gel, wherein the third polypeptide has a mass fingerprint similar to a mass fingerprint of *M. tuberculosis* Ag85B protein (Rv 1866c), and
  - (iv) a fourth polypeptide having a molecular weight of about 10 kDa as measured following electrophoresis on a sodium dodecylsulfate (SDS) polyacrylamide gel, wherein the fourth polypeptide has a mass fingerprint similar to a mass fingerprint of *M. tuberculosis* CFP10 protein (Rv3874), and

( i ) a fifth polypeptide having a molecular weight of about 6 kDa as measured following electrophoresis on a sodium dodecylsulfate (SDS) polyacrylamide gel, wherein the fifth polypeptide has a mass fingerprint similar to a mass fingerprint of *M. tuberculosis* ESAT-6 protein (Rv3875).

13. The liposome formulation according to any of the preceding claims, wherein at least one of the following antigens of *Mycobacterium tuberculosis*, or fragment thereof, is present: HSP70, 38 kDa protein and Ag85B.
14. The liposome formulation according to any of the preceding claims, comprising one or more mycolic acids and/or a sugar-conjugated mycolate, preferably trehalose dimycolate and/or a glycolipid, preferably liporabinomannan.
15. The liposome formulation according to any of the preceding claims, additionally comprising one or more non-ionic surfactants.
16. The liposome formulation according to any of the preceding claims, additionally containing one or more salts or a solution thereof, whereby the salt is preferably sodium chloride.
17. The liposome formulation according to any of the preceding claims, wherein the liposome formulation is freeze-dried.
18. A suspension, wherein the liposome formulation of any of the preceding claims is reconstituted in a solvent, wherein the solvent is preferably aqueous, and more preferably is or comprises physiological serum.
19. A pharmaceutical composition comprising the formulation according to any of claims 1 to 17 or the suspension according to claim 18, and a pharmaceutically acceptable carrier or diluent, and/or a pharmaceutically acceptable adjuvant.
20. The liposome formulation according to any one or more of claims 1 to 17, the suspension according to claim 18, or the pharmaceutical composition according to claim 19 for use in a method of treatment of the human or animal body by therapy.

21. The liposome formulation, suspension or pharmaceutical composition according to claim 20 for use in a method of treating or preventing tuberculosis.
22. The liposome formulation, suspension or pharmaceutical composition according to claim 21, selected from the following:
  - a) for use in a method of prevention of active tuberculosis in individuals with a latent tuberculosis infection;
  - b) for use in a method of primary prophylaxis of tuberculosis in order to prevent infection of individuals who had been exposed to the disease, but are not yet infected, or
  - c) for use in a method of treating or preventing latent tuberculosis.
23. The liposome formulation, suspension or pharmaceutical composition according to any of claims 20 to 22 for administration to the human body in a dose comprising 1 to 1000, preferably 3 to 250, more preferably 4 to 80, and most preferably about 5, about 25 or about 50 µg/dose FCMtb.
24. The liposome formulation, suspension or pharmaceutical composition according to any of claims 20 to 22 for administration to the human body in a single oculation dose of 25 µg FCMtb.
25. The liposome formulation, suspension or pharmaceutical composition according to any of claims 20 to 24 for use in combination therapy, which preferably comprises an antibiotic, more preferably one or more of isoniazide and an ansamycine, whereby the ansamycine is most preferably rifampicin.
26. The liposome formulation, suspension or pharmaceutical composition of claim 24 for use in adjunctive therapy.
27. The liposome formulation, suspension or pharmaceutical composition according to claim 26 for administration in adjunctive therapy to an HIV positive human subject.
28. The liposome formulation, suspension or pharmaceutical composition according to claim 24 for administration to an HIV negative human subject.

Figures:




Figure 1




Figure 2




Figure 3






Figure 4

4/15




Figure 5a




Figure 5b




Figure 5c




Figure 5d




Figure 5e




Figure 5f

6/15




Figure 6




Figure 7a




Figure 7b




Figure 7c




Figure 7d




Figure 8




Figure 9








Figure 10a

12/15

### PPD



### 85B




Figure 10b




Figure 11




Figure 12




Figure 13

# INTERNATIONAL SEARCH REPORT

International application No PCT/EP2012/050080
---

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> INV. A61K9/127      A61K47/26      A61K39/04      A61P31/06      A61K31/06 ADD.				
According to International Patent Classification (IPC) or to both national classification and IPC				
<b>B. FIELDS SEARCHED</b>				
Minimum documentation searched (classification system followed by classification symbols) A61K				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, EMBASE, BIOSIS, FSTA				
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
A	EP 1 690 549 A1 (ARCHIVEL FARMA SL [ES]) 16 August 2006 (2006-08-16) cited in the application claims 1, 9, 11, 12 examples 1-3	1-29		
A	----- EP 2 090 318 A1 (ARCHIVEL FARMA SL [ES]) 19 August 2009 (2009-08-19) cited in the application claims 1, 8, 12 examples 1-2 -----	1-29		
	----- -/--			
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.				
* Special categories of cited documents : <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; vertical-align: top;">                     "A" document defining the general state of the art which is not considered to be of particular relevance                      "E" earlier document but published on or after the international filing date                      "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)                      "O" document referring to an oral disclosure, use, exhibition or other means                      "P" document published prior to the international filing date but later than the priority date claimed                 </td> <td style="width: 50%; border: none; vertical-align: top;">                     "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention                      "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone                      "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.                      "&amp;" document member of the same patent family                 </td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family			
Date of the actual completion of the international search	Date of mailing of the international search report			
22 February 2012	02/03/2012			
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer  Peris Antoli, Berta			

INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2012/050080

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>CARDONA P-J ET AL: "Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronic infection in a murine model of tuberculosis", VACCINE, ELSEVIER LTD, GB, vol. 23, no. 11, 3 February 2005 (2005-02-03), pages 1393-1398, XP004718831, ISSN: 0264-410X, DOI: DOI:10.1016/J.VACCINE.2004.09.008 abstract page 1394, column 2, paragraph 2 page 1396, column 1, paragraph 1 page 1397, column 2, paragraph 4 - page 1398, column 1, paragraph 1 -----</p>	1-29
A	<p>MOHAMMED A R ET AL: "Increased potential of a cationic liposome-based delivery system: Enhancing stability and sustained immunological activity in pre-clinical development", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 76, no. 3, 1 November 2010 (2010-11-01), pages 404-412, XP027503465, ISSN: 0939-6411, DOI: DOI:10.1016/J.EJPB.2010.09.008 [retrieved on 2010-09-25] abstract page 405, column 1, paragraph 5 - column 2, paragraph 2 page 406, column 2, paragraph 4 - page 407, column 1, paragraph 1 figures 1, 2a, 4a ----- -/--</p>	1-29

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2012/050080

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>MOHAMMED A R ET AL: "Lyophilisation and sterilisation of liposomal vaccines to produce stable and sterile products", METHODS : A COMPANION TO METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC., NEW YORK, NY, US, vol. 40, no. 1, 1 September 2006 (2006-09-01), pages 30-38, XP024908469, ISSN: 1046-2023, DOI: DOI:10.1016/J.YMETH.2006.05.025 [retrieved on 2006-09-01] abstract page 32, column 2, paragraph 1 - page 33, column 1, paragraph 2 page 34, column 1, paragraph 1 - column 2, paragraph 2 page 35, column 1, paragraph 3 figure 2a tables 1,2</p> <p style="text-align: center;">-----</p>	1-29
A	<p>CROWE J H ET AL: "INTERACTIONS OF SUGARS WITH MEMBRANES", BIOCHIMICA ET BIOPHYSICA ACTA, ELSEVIER, NL, vol. 947, no. 2, 9 June 1988 (1988-06-09), pages 367-384, XP008033012, ISSN: 0006-3002 page 372, column 2, paragraph 2 - page 373, column 2, paragraph 2 page 378, column 1, paragraph 5 - column 2, paragraph 1</p> <p style="text-align: center;">-----</p>	1-29
A	<p>ZADI B ET AL: "A NOVEL METHOD FOR HIGH-YIELD ENTRAPMENT OF SOLUTES INTO SMALL LIPOSOMES", JOURNAL OF LIPOSOME RESEARCH, TAYLOR &amp; FRANCIS, PHILADELPHIA, PA, US, vol. 10, no. 1, 1 February 2000 (2000-02-01), pages 73-80, XP001023103, ISSN: 0898-2104 abstract page 76, paragraph 2 - page 77, paragraph 1 figures 1-2</p> <p style="text-align: center;">-----</p>	1-29
A	<p>WO 2009/089535 A2 (US GOV HEALTH &amp; HUMAN SERV [US]; SABLE SURAJ [US]; PLIKAYTIS BONNIE B) 16 July 2009 (2009-07-16) claims 1,8,10,11-13</p> <p style="text-align: center;">-----</p> <p style="text-align: center;">-/--</p>	1-29



**INTERNATIONAL SEARCH REPORT**

International application No PCT/EP2012/050080
---

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>ORME ET AL: "Preclinical testing of new vaccines for tuberculosis: A comprehensive review",  VACCINE, ELSEVIER LTD, GB,  vol. 24, no. 1,  9 January 2006 (2006-01-09), pages 2-19,  XP025151264,  ISSN: 0264-410X, DOI:  DOI:10.1016/J.VACCINE.2005.07.078  [retrieved on 2006-01-09]  page 6, column 2, paragraph 4 - page 7,  column 2, paragraph 3  page 12, column 2, paragraph 6 - page 13,  column 1, paragraph 4  -----</p>	1-29

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/EP2012/050080
---

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 1690549	A1	16-08-2006	AT 428442 T 15-05-2009
			AU 2004285305 A1 12-05-2005
			BR PI0415695 A 26-12-2006
			CA 2543659 A1 12-05-2005
			CN 1874785 A 06-12-2006
			DK 1690549 T3 17-08-2009
			EP 1690549 A1 16-08-2006
			ES 2231037 A1 01-05-2005
			ES 2325835 T3 21-09-2009
			HK 1098362 A1 12-02-2010
			JP 2007509910 A 19-04-2007
			KR 20060126963 A 11-12-2006
			MA 28121 A1 01-08-2006
			NZ 546715 A 30-05-2008
			PT 1690549 E 20-07-2009
			RU 2341287 C2 20-12-2008
			US 2007269501 A1 22-11-2007
			WO 2005042013 A1 12-05-2005
ZA 200604234 A 28-11-2007			
EP 2090318	A1	19-08-2009	AU 2007316091 A1 08-05-2008
			CA 2667965 A1 05-08-2008
			CN 101600455 A 09-12-2009
			EP 2090318 A1 19-08-2009
			ES 2307402 A1 16-11-2008
			JP 2010508254 A 18-03-2010
			KR 20090087874 A 18-08-2009
			US 2010068258 A1 18-03-2010
			WO 2008053055 A1 08-05-2008
WO 2009089535	A2	16-07-2009	CN 101969976 A 09-02-2011
			EP 2244720 A2 03-11-2010
			US 2011027349 A1 03-02-2011
			WO 2009089535 A2 16-07-2009